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Introduction 
1.1 Glioblastoma multiforme (GBM) 
1.1.1 History  
All intrinsic brain tumours stemming from non-neural glial tissues are called glioma. 
Glia cells naturally surround neurons and exhibit various supportive functions such as 
holding them in place (Glia is a Greek word, which means glue). Genetic alterations 
may lead to their dedifferentiation and malignant transformation [5].  
In 1867 Rudolf Virchow conceived the idea of the intestinal origin of brain tumours [6]. 
The first reported intracranial surgery for cerebral glioma was published in 1884 by 
Bennett and Godlee [7]. The patient did well initially, but eventually postoperative her-
niation and meningitis resulted in death. Further ineffective approaches included de-
compression of the brain by a subtemporal resection of the bone [8] and preoperative 
trial of potassium iodide [9]. The first breakthrough in understanding brain tumours was 
achieved by a systematic histological classification of gliomas, which was published in 
1926 by Bailey and Cushing [10]. They found correlations between the histology of the 
tumour, the operative procedure, and the overall survival rate of the patients. The most 
frequently occurring subtype of glioma with a mixed morphology and the poorest prog-
nosis has been named glioblastoma multiforme.  
In the following years GBM was further classified into two groups: primary and second-
ary GBM [11, 12]. Over 90% of the fast-growing primary GBM cases develop de novo 
in elderly patients, while younger patients in the range of 30–50 years tend to have a 
less malignant type of GBM with different genetic and epigenetic profiles. This type, 
known as secondary GBM develop from more benign tumours such as low-grade dif-
fuse astrocytoma or anaplastic astrocytoma [13]. 
A newer attempt to classify GBM in subtypes according to distinct molecular character-
istics is revealed by genome-wide expression studies. Four subtypes have been distin-
guished: classical, mesenchymal, proneural, and neural GBM [14].  
Although the number of scientific publications concerning GBM exploded during the 
last 10 years (2004 ~700 publications, 2014 ~2300 publications), there have been only 
marginal benefits for the patients. GBM is still exceedingly lethal with a bad prognosis. 
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1.1.2 WHO classification 
An international working group of 25 pathologists and geneticists convened at the 
German Cancer Research Center in Heidelberg in November 2006 to form the fourth 
edition of the WHO classification of tumours of the central nervous system. Underlying 
a histological malignancy scheme, these tumours were graded into four groups (WHO 
Grades I–IV). Since Grades I and II subsume benign tumours with a good prognosis, 
Grades III and IV are reserved for lesions with histological malignancy. The most fre-
quently occurring histological types of gliomas include astrocytoma (Grades I–IV), oli-
godendroglioma (Grades II–III), and oligoastrocytoma (Grades II–III) [15]. Glioblastoma 
multiforme is classified as Grade IV astrocytoma, which is marked by rapid disease 
evolution and fatal outcomes [16]. 
1.1.3 Epidemiology 
The incidence of GBM increases with age: the peak is reached by people belonging to 
the age group between 75–84 years [17]. Since elderly patients are less likely to have 
a histological diagnosis, the incidence of GBM in this group might be underestimated. 
The age-adjusted incidence of GBM ranges from 0.59 (Korea 2005), 3.19 (USA 2006–
2010) to 3.69 (Greece 2005–2007) per 100,000 persons [15]. These incidence rates 
have been stable over the periods assessed [18]. In the USA all gliomas are much 
more common in non-Hispanic white people than other entities [19]. The fact that the 
incidence of glioma is 50% greater in adult men than in women and that there is a 
higher risk for postmenopausal women leads to the hypothesis of a protective influence 
of sexual hormones on the pathogenesis of GBM [17, 20]. Only 0.05% to 4.7% of pa-
tients with GBM have survived over the past five years’ diagnosis [19]. 
1.1.4 Etiology 
Even though GBM is the most common brain tumour in adults, less is known about the 
etiology of such tumours. Epidemiological data from A-bomb studies suggest a linear 
dose-dependent association between ionizing radiation and all kinds of malignant brain 
tumours [21]. While the risk for gliomas is doubling, meningioma and acoustic neuroma 
risk is even higher [22]. According to these results, several studies tried to find an as-
sociation between CT scans and the risk of getting a brain tumour [23-25]. They show 
that the risk significantly increases at a minimum dose of ~ 10-50 mSv. In comparison, 
the X-ray dose of one single CT scan is estimated as ~ 4 mSv on average [25]. Taken 
together, radiation-induced malignant gliomas pose an evident, but relatively rare, iat-
rogen complication. 
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Since epidemiological data showed an inverse correlation between allergic hypersensi-
tivity reactions and risk of glioma, several groups investigate a potential immunological 
etiology [26-28]. A meta-analysis in published in 2007 showed that allergic dispositions 
reduce glioma risk by nearly 40% [29]. Newer results indicate a protective influence of 
varicella-zoster [30] and human cytomegalovirus [31] in the pathogenesis of human 
brain tumours. 
Only 1% of all glioma cases are caused by dominant monogenetic disorders including 
neurofibromatosis type 1 and type 2 (NF1, NF2), tuberous sclerosis (TSC), Lynch syn-
drome (HNPCC), Li-Fraumeni syndrome, Melanoma-neural system tumour syndrome, 
and Maffucci syndrome. The carriers of HNPCC and Li-Fraumeni syndrome are pre-
disposed for GBM [32]. Besides monogenetic predispositions, DNA single nucleotide 
polymorphisms (SNPs) are found to significantly correlate with glioma risks. Some 
candidate genes are: TERT (5p15.33), two SNPs in EGFR (7p11.2), CCDC26 
(8q24.21), CDKN2B (9p213), PHLDB1 (11q23.3), TP53 (17p13.1), and RTEL1 
(20q13.33) [33]. 
A possible relationship between radiofrequency fields of cellular phones and glioma 
incidence was suggested by the International Agency for Research on Cancer (IARC) 
in 2011 [34]. Further epidemiological studies find no sudden increase in glioma rates, 
indicating inadequate evidence for this hypothesis [18, 35].  
1.1.5 Molecular features of GBM 
During the last few decades, intense molecular research has discovered a confusing 
amount of genetic alterations and pathway aberrations concerning GBM (Fig. 1.1). A 
prognostic and predictive clinical value of some of these alterations has already been 
confirmed—e.g., O6-alkylguanine DNA alkyltransferase (MGMT)-methylation status and 
Isocitrate dehydrogenase 1 (IDH1) mutation. GBM has hyperdiploid and complex kary-
otypes [36]. Since they are “multiforme”, these biomolecular results are important in a 
process where a deeper understanding might help to individualize tumour therapy. This 
chapter focuses on the main results and is not exhaustive. 
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1.1.5.1 Isocitrate dehydrogenase 1 (IDH1) 
IDH1 is an enzyme of the citric acid cycle and very frequently mutated in younger pa-
tients with low-grade glioma and secondary GBM (>80%), but rarely in primary GBM 
(<5%) [37]. Since 2008, when IDH1 mutations were discovered first [38], many studies 
have confirmed its role as a genetic marker to reliably distinguish primary from second-
ary GBM [14, 37, 39]. Molecular research on IDH1 mutation is still going on: it has been 
shown that the IDH1 mutation on the active site (R132H) dominantly inhibits endoge-
nous IDH1 activity, which decreases α-ketogluterate and increases cellular HIF-1α pro-
tein levels [40]. This mutation leads to increased conversion of 2-hydroxygluterate, in-
stead of α-ketogluterate [41]. Newer results show an influence of the oncometabolite 2-
hydroxygluterate on epigenetic events and tumourigenesis [42]. Besides its positive 
prognostic value, further research is still needed to show the impact of IDH1 mutations 
in tumour biology.  
1.1.5.2 Epidermal growth factor receptor (EGFR) pathway alterations 
EGFR, as a member of the ERBB family, is a receptor tyrosine kinase on the cell sur-
face where it physiologically initiates cell proliferation, differentiation, and survival when 
activated by specific ligands (Fig. 1.2). The binding of the EGF ligand to EGFR acti-
vates the RTK/RAS/PI3K pathways. Besides a common aberrant amplification of 7p11 
Figure 1.1: Overview of genetic alterations in the development of primary and secondary GBM: Vari-
ous amplifications, deletions, and mutations can lead to malignant transformation. The genetic profile differs 
between primary and secondary GBM. Primary GBM develops de novo from glial progenitor cells, whereas 
secondary GBM grows from lower-grade tumours, such as diffuse astrocytoma or oligodendroglioma.  
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- EGFR (~70%), GBM may exhibit a functional and permanently activated mutant EG-
FRvIII (~50%), resulting from the deletion of exons 2–7 [43]. Since EGFRvIII is phos-
phorylized by EGFR, both EGFR amplification and EGFRvIII mutation are mostly coex-
pressed and result in a EGFRvIII-STAT3 nuclear complex formation, leading to in-
creased tumour proliferation [44]. However, the prognostic value of EGFR and EG-
FRvIII alterations seems to be less evident [45, 46]. 
 
 
 
 
 
 
 
Having a closer look at the downstream signalling processes of the EGFR-pathway, 
more alterations can be found in GBM: 
The phosphatase and tensin homolog (PTEN) is a tumour suppressor, which physio-
logically dephosphorylates PIP3 to PIP2 and therefore negatively regulates the 
Figure 1.2: EGFR pathway in GBM. Ligand binding to EGFR surface receptors leads to activation of 
PI3K/AKT and Ras/Raf/MEK/MAPK pathways, inducing growth advantage for the cells. PI3K encom-
passes two subunits, the catalytic subunit p110α and the regulatory subunit p85α. EGFRvIII is a mu-
tant form of EGFR in GBM with oncogenic potential through permanently active EGFR-signalling. 
PTEN acts as a tumour suppressor by inhibiting AKT, and NFKBI negatively regulates NF-κB by bind-
ing it. NF1 is able to increase the GTPase activity of Ras and thereby stops MAPK signalling. 
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PI3K/Akt pathway. Loss of PTEN expression due to deletion, mutation, or methylation 
affects 5–40% of all GBM cases [47, 48], and leads to accumulation of PIP3 and acti-
vation of the oncogenic Akt/mTOR pathway. Since the prognostic relevance of PTEN 
mutation in GBM is not clear, it is shown to be a negative prognostic factor in anaplas-
tic astrocytoma (WHO III) [49]. 
Beyond that, mutations of the subunits of PI3K can be found in GBM. The catalytic 
subunit p110α, encoded by PIK3CA, is affected in 7–10 %, while the regulatory subunit 
p85α, encoded by PIK3R1, is affected in 7–8 % of the cases [50]. 
The protein complex NF-κB is included in the transcription of immune modulating 
genes and has an oncogenic impact on tumour cells, when permanently activated. Be-
sides an EGFR-triggered increase in NF-κB activity, the constitutive activation of NF-κB 
through deletion of the inhibitor NFKBIA might play an important role in GBM patho-
genesis [51]. The downregulation of NFKBIA, especially with a recently identified poly-
morphism [52], is associated with lower survival, behaviour, and response to chemo-
therapeutic drugs, especially Temozolomid [51]. 
The GTP-binding oncogene Ras is a molecular switch, which, when activated, leads to 
increased cellular proliferation. Even though many malignant tumours exhibit a perma-
nently active Ras-mutant, mutations of Ras in GBM is a rarely seen alteration [53]. 
Nevertheless, deletions in NF1, which terminates Ras signalling by inducing its 
GTPase activity, have been observed [14]. In vitro experiments indicate the influence of 
YKL-40 protein in activating Akt and MAPK pathways [54, 55]. 
1.1.5.3 P53 and Rb pathway alterations 
Because of this important protective function, the powerful tumour suppressor protein 
p53 is also called the “guardian of the genome”. Upon DNA damage, p53 activates 
several protective pathways associated with cell cycle arrest or induction of apoptosis 
under severe damage. HIPK2 is also involved in this pathway by phosphorylating p53 
at Ser46 [56]. The expression of mutant p53 is common in cancer; it leads to increased 
resistance to radio and chemotherapy. In GBM, amplification of MDM2 (13%) [57] and 
deletion of CDKN2A (49%) [58, 59] result in downregulation of the p53-pathway. MDM2 
amplification might be associated with a shorter survival time [57]. Additionally, TP53 is 
often found to be silenced in GBM by mutations (31–38%) and hypermethylation 
events [50, 60]. The prognostic impact has still remained controversial [57, 61]. 
Rb signalling is decreased through deletion of CDKN2, amplification of CDK4 (18%), 
CDK6 (1%) and CCND2 (2%), as well as mutation or deletion of Rb1 (11%) [62]. In 
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addition, a loss of the tumour suppressors INK4A/ARF in primary GBM leads to down-
regulation of Rb and p53 activities [63]. 
1.1.5.4 microRNAs 
Newer results indicate that non-protein-coding short microRNAs (miR) molecules are 
included in the pathogenesis of GBM concerning proliferation, invasion, stem cell be-
haviour and angiogenesis. Especially the oncogenic miR-21 is highly expressed in 
cancer and targets PTEN and other tumour suppressors (TIMP3, PDCD4) [64]. Exper-
imental evidence shows that downregulation of miR-21 leads to decreased glioma pro-
liferation in vivo through PDCD4 upregulation [65]. Another promising candidate is miR-
7, which inhibits EGFR by binding to its 3'-UTR. Independent of its EGFR inhibition, 
miR-7 can also inhibit the downstream Akt pathway [66]. Moreover, microRNAs are 
used to get the expression profiles of GBM subtypes and thus have prognostic rele-
vance [67]. 
1.1.5.5 O-6-methylguanine-DNA methyltransferase (MGMT) 
MGMT is an enzyme which usually repairs DNA in response to alkylating stress [39, 
68]. In about 40% of primary GBM and over 70% of secondary GBM, MGMT is epige-
netically hypermethylated [69]. This eventually inactivates the enzyme and increases 
the vulnerability to Temozolomide (TMZ), the most common chemotherapeutic sub-
stance in GBM therapy. When spontaneously activated, the prodrug TMZ is able to 
damage the DNA at guanine on the position O-6 by alkylation [70]. Alkylated O6-
methyl-guanine results in DNA strand breaks and eventually leads to cell-cycle arrest 
and cell death. All in all, GBM patients with MGMT promoter hypermethylation exhibit a 
better prognosis via an improved response to TMZ [68]. 
1.1.6 Clinical signs 
GBM is a fast-growing tumour with a low metastatic potential [71]. Clinical signs de-
pend on the localization in the brain, edema, blood supply of the tumour, and re-
sistance or limited response to therapy. Initial symptoms are not specific; they are 
caused by intracranial hypertension related to the amount of edema and lead to head-
ache, nausea and vomiting. These symptoms can easily be misinterpreted as infec-
tions or circulatory and inflammatory diseases [72]. Newly appeared seizures are al-
ways suspicious for brain tumours [73]. Depending on tumour location (infra or su-
pratentorial) and migration behaviour, 30-40% of brain tumour patients develop neuro-
logical symptoms such as hemiparesis, speech and memory problems, nystagmus, 
visual changes, and other dysfunctions related to brain damage and cranial nerve inju-
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ries. The most favourable location for GBM is the white matter of the frontal lobe (40%), 
and temporal (29%), parietal (14%), and occipital lobes (3%) [74]. In particular, a tu-
mour in the frontal lobe bears the risk of personality change, disinhibited behaviour, 
and a deficient mood. Unusual localization in the spinal cord and infratentorial edema 
shows a severe risk of lower brain herniation of the brainstem and upper cervical spinal 
cord, which are responsible for important vital functions such as respiration, cardiac 
function, and vomiting [75]. Patients undergoing chemotherapy may develop nausea 
and vomiting due to unspecific cytotoxicity of the drugs. 
1.1.7 Treatment options 
The treatment of GBM concentrates on surgery, radiation, and chemotherapy in order 
to regress the tumour and provide a longer survival with less symptoms. Unfortunately, 
there is no possible cure at present. Preoperative intracranial hypertension can be con-
trolled with high doses of corticosteroids. The decision to perform an elective operation 
for a suspicious brain tumour depends on the diagnosis, age of the patient, and locali-
zation. There is evidence that intraoperative use of 5-ALA and MRT, which is used to 
help localize the tumour, increases the success of the operation [76]. Since GBM infil-
trates the brain, there is no chance of achieving a complete resection of all malignant 
cells. The intention is to resect as much as possible without damaging the functional 
brain matter. Radiotherapy helps to control the remaining local tumour mass. The best 
results are obtained with 54–60 Gy, while doses over 60 Gy show high side-effects for 
the patient [77].  
Besides surgery and radiotherapy, the patient is treated with Temozolomide (TMZ), an 
alkylating agent. The Cochrane meta-analysis shows that during TMZ treatment the 
overall survival and the progression-free survival of a defined cohort significantly in-
crease in the primarily diagnosed, but not in recurrent, GBM [78]. Also, the MGMT 
promoter methylation status is an independent favourable prognostic factor, which in-
creases the median survival from 15.3 to 21.7 months upon TMZ treatment [79]. An-
other alkylating drug for local intra-cavity treatment of GBM is carmustine, which is im-
planted into the resection bed during surgery. A positive effect on survival is shown for 
primary diseases [80]. Cilengitide, an inhibitor of the integrins, shows no benefit for the 
patients [81]. Since they increase the median progression-free survival from 6.2 to 10.6 
months, therapies with the monoclonal antibody Bevacizumab, a VEGF inhibitor, are 
evident for the treatment of GBM [82, 83]. Newer approaches focus on the altered 
pathways in GBM. Rindopepimut is an EGFRvIII-targeting vaccine, which already 
shows an improved overall survival in Phase II studies [84]. Dacomitinib is an EGFR 
tyrosine kinase inhibitor. Early studies indicate its positive effect on EGFR amplified 
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cells with and without EGFRvIII mutation [85]. Since virus infections seem to play a role 
in GBM pathogenesis, anti-viral treatments are also in focus [31]. Recent studies have 
identified tumour stem cell markers (e.g., CD133+ and L1CAM), but their therapeutic 
relevance is still unclear [86]. A deeper understanding of the biomolecular pathways 
might help to find new ways to treat patients suffering from GBM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacodrug Mechanism Reference 
Temozolomid DNA alkylation [70, 78, 79] 
Carmustine DNA alkylation [80] 
Cilengitide Integrin inhibitor [81] 
Bevacizumab VEGF inhibitor [82, 83] 
Rindopepimut EGFRvIII-targeting vaccine [84] 
Dacomitinib EGFR inhibitor [85] 
Table 1: Overview of pharmacological approaches of GBM treatment. Besides the 
widely used DNA-alkylating Temozolomid, many other drugs for GBM therapy are still 
under investigation. Some of them have different targets, such as integrin, VEGF, and 
EGFR inhibitors, as well as the specific mutant EGFRvIII, which seems to be a rea-
sonable target for pharmacological treatment. 
Table 1: Overview of current pharmacological approaches of GBM treatment 
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1.2 Homeodomain-interacting protein kinase 2 (HIPK2) 
1.2.1 What is HIPK2? 
HIPK2 is serine/threonine kinase and belongs to the HIPK family/DYRK subfamily, to-
gether with HIPK1, HIPK3, and HIPK4. In 1998 a yeast two-hybrid screen discovered 
HIPK1-3 as a novel family of co-repressors for homeodomain transcription factors [87]. 
Since then, many publications have shown that especially HIPK2 holds a larger num-
ber of cellular functions such as regulation of the transcription including cell death, de-
velopment, differentiation, and segmental identity. HIPK1-3 shows > 90% homology, 
where HIPK4 remains a relative with only 50% structural resemblance [88]. The fact 
that HIPKs are evolutionarily conserved among vertebrates leads to the supposition 
that mutations may lead to a non-viable form. Since HIPK2-/- mice show no morpholog-
ical deficiencies, double knockout mice HIPK1-/- and HIPK2-/- exhibit severe neurologi-
cal problems probably due to defective proliferation in the neural fold. Such experi-
mental data suggests that HIPK1 is able to take over several functions of HIPK2 [89]. 
The impact of HIPK2 on the central nervous system can further be observed in the de-
ficient survival of midbrain dopamine neurons upon HIPK2 knockout. HIPK2-/- mutants 
show psychomotor abnormalities due to decreased TGF-β signalling [90]. HIPK2 
mRNA is expressed in most human adult tissues [91], particularly in retina, muscle, and 
neural tissues [92]. An increased expression of HIPK2 and its interaction partner, 
CtBP2 is also detectable after traumatic brain injuries in the peritrauma brain cortex 
[93]. Newer results could show a phosphorylation of H2B by HIPK2 at the midbody, 
which is shown to be required for a faithful cytokinesis. Loss of HIPK2 by RNA interfer-
ence results in cytokinesis failure and tetraploidization, indicating a role in tumourigen-
icity [94]. 
1.2.2 Structure and localization of HIPK2 
The human form of HIPK2 has 1,198 amino acids. Its protein kinase domain is located 
at the N-terminus, which is followed by an interaction domain for transcription factors. 
The protein can be SUMOylated at lysine 25, exhibits a SUMO-binding motif (SIM) and 
nuclear localization signals (NLS1 and NLS2) as well as two PEST domains that are 
rich in proline, glutamic acid, serine, and threonine. The C-terminus is characterized by 
S, Q, and A repeats and an auto-inhibitory domain which is cleaved by caspase-6 upon 
early induced p53-activation [95]. The gene encoding HIPK2 is located in chromosome 
7q32-q34 [96]. 
Most of the HIPK1-3 proteins are localized in nuclear speckles in HIPK domains [97]. 
They, however, show an overlap with Pc2 in polycomb nuclear bodies and PML nucle-
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ar bodies. Upon DNA-damage, an auto-regulatory feedback loop between HIPK2 and 
its E3 ligase Pc2 is established, thereby leading to transcriptional activity [98]. Even 
though architecturally independent, PML is still required for the kinase activity of HIPK2 
[97]. Kinase defective K221A mutants lose their ability to localize in nuclear speckles 
and therefore spread throughout the whole nucleoplasm. Also, two nuclear localization 
signals (NLS1, NLS2) and the SIM region are essential for the nuclear localization of 
HIPK2 [99]. Despite the fact that most of HIPK2 are in the nucleus, small fractions can 
also be found in cytoplasms [100]. Their functions, however, remain unclear. 
1.2.3 Role of HIPK2 in DNA damage response and cell death 
Upon DNA damage, HIPK2 is involved in programmed cell death through p53-
dependent and p53-independent pathways. 
1.2.3.1 HIPK2-mediated p53-dependent pathways upon DNA damage 
The tumour suppressor p53 can promote either cell cycle arrest or apoptosis, depend-
ing on the severity of the DNA damage (Fig. 1.3). In unstressed cells a complex be-
tween p53 and its E3 ubiquitin ligase MDM2 leads to nuclear export and proteasomal 
degradation of p53 [57]. Upon severe DNA damage, stabilized HIPK2 is able to bind 
p53 through the C-terminal domain of p53. PML additionally facilitates the p53-HIPK2 
complex formation in nuclear bodies by recruiting various enzymes [97, 101]. This pro-
tein-binding leads to phosphorylation of p53 at Ser46, which results in the CBP-
mediated acetylation of p53 at Lys382 [56, 102, 103]. Activation of apoptotic factors, 
such as PIG3, p53AIP, BAX, NOXA and PUMA, is a consequence of the p53 transcrip-
tional activity [56]. The phospho-specific isomerase PIN1 is also involved in p53 accu-
mulation and activation, since it binds to phosphorylated Ser46p53 and mediates con-
formational changes [104, 105]. PIN1 modulates Siah1-HIPK2 interaction and hence, 
stabilization of HIPK2 [104, 105]: Upon DNA-damage HIPK2 is able to autophosphory-
late at Thr880/Ser882 and it was shown that this autointeraction has an impact on p53 
phosphorylation and thus DNA-damage induced apoptosis in cellulo [104]. In detail, the 
autophosphorylation enables PIN1 to bind HIPK2 and this interaction prevents HIPK2 
from polyubiquitination and thus degradation. Additionally, HIPK2 decreases MDM2 
levels and thus antagonizes nuclear export and ubiquitination of p53 [106]. Cofactors of 
the HIPK2-mediated p53Ser46 phosphorylation are Axin, Daxx, p53DINP1/TP53INP1, 
and Sp100 [107]. Caspase-6, a p53-induced protein, binds to the autoinhibitory domain 
of HIPK2, which initially potentiates p53Ser46 phosphorylation and induction of the 
apoptotic machinery. Later, C-terminally truncated HIPK2 is eliminated by proteasomal 
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degradation [95]. Upon non-severe DNA damage, the inhibitor p21 is activated through 
the HIPK2/PCAF-mediated acetylation of p53, which leads to cell cycle arrest [108]. 
 
 
 
 
 
1.2.3.2 HIPK2-mediated p53-independent pathways upon DNA damage  
Besides p53Ser46 phosphorylation, HIPK2 has other mechanisms to induce apoptosis 
and promote its work as a tumour suppressor. The phosphorylation of the anti-
apoptotic CtBP at Ser422 by HIPK2 leads to its proteasomal degradation and thus in-
creases the transcription of pro-apoptotic genes such as BAX and NOXA [109]. Fur-
ther, HIPK2 is able to phosphorylate and activate NLK upon Wnt signalling, which re-
sults in multiple c-Myb phosphorylations, proteasomal degradation and G1 arrest [110]. 
It has been shown that apoptosis is induced upon TGF-β stimulation, leading to HIPK2-
mediated activation of JNK by using DAXX, MAPKK4, and MAPKK7 [111]. In addition, 
the phosphorylation of the anti-apoptotic isoform ∆Np63α by HIPK2 has been observed 
to contribute to its degradation [112].  
1.2.4 HIPK2 alterations in cancer 
Since HIPK2 is a key protein in the responses to DNA damage, apoptosis, hypoxia, 
and cytokinesis, it is not surprising that its alteration might be a driver for proliferative 
diseases. 
1.2.4.1 Downregulation of HIPK2 in cancer 
Various analyses could show that the expression of HIPK2 is downregulated in neo-
plastic thyroid carcinoma and breast carcinoma [92], and in well-differentiated thyroid 
carcinomas through galectin-3 overexpression [113].  
Figure 1.3: HIPK2-mediated p53-dependent pathway upon severe DNA damage. Severe damage 
stabilizes HIPK2, which phosphorylates p53 at Ser46 in PML nuclear bodies. Subsequent CBP-
mediated p53 acetylation fully activates p53 and its pro-apoptotic genes, leading to apoptosis. 
Caspase-6 can truncate HIPK2 at its C-terminus, thereby potentiating its kinase activity. 
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Also, the stabilization of HIPK2 upon DNA damage through MYCN activation increases 
the susceptibility of neuroblastoma to apoptosis [114]. 
A correlation between HIPK2 expression and the survival of 80 patients with primary 
colorectal carcinoma has been suggested. Patients with decreased HIPK2 expression 
exhibited a lower outcome through growth advantages of the tumour cells [115]. Wild-
type HIPK2 leads to p53-mediated depletion of β4-Integrin, where the depletion of 
HIPK2 strongly results in β4 Integrin upregulation as well as phosphorylation of MAPK 
and Akt, which are both involved in invasion and metastasis [116]. Metastasis and re-
sistance to chemotherapy in bladder cancer are also promoted by downregulation of 
HIPK2 [117, 118]. Further, a HIF-mediated chemoresistance of hepatocellular carcino-
ma cells through upregulation of WSB-1 and accordingly degradation of HIPK2 have 
been observed [119]. 
It has been reported that carcinogenesis treatment of wild-type, HIPK2+/- and HIPK2-/- 
mutants results in more skin cancer formations in HIPK2-depleted mice [120]. Patho-
physiological mechanisms of skin cancer development can further be explained by the 
upregulation of the β-Catenin/LEF1-pathway upon HIPK2 depletion. The consequence 
is a more rapid G1-S transition in cell cycle, epidermal stem cell expansion [120], and 
VEGF upregulation [121] to promote carcinogenesis. In addition, there is an influence 
of the viral oncogene HPV23 E6, which acts as a cofactor and targets HIPK2 upon 
massive UVB-radiation, thereby preventing p53Ser46 phosphorylation [122]. 
Another example shows the impact of HIPK2 mislocalization in the context of leukemo-
genesis: RUNX1/PEBP2-β phosphorylation during hematopoiesis is normally mediated 
by HIPK2 in the nucleus. The oncogenic protein PEBP2-β-SMMHC disrupts RUNX1 
phosphorylation by passing over HIPK2 to cytoplasmatic filaments [123]. Incidentally, 
two missense mutations (R868W and N958) in the SRS domain have been shown to 
be mutated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), 
which affects MDM2 and RUNX1-mediated transcription as well as their subcellular 
localization in speckles [124]. Moreover, a loss of heterozygosity (LOH) has been found 
in radiation-induced lymphoma, which indicates a function of HIPK2 as a haploinsuffi-
cient suppressor gene [125]. 
1.2.4.2 Upregulation of HIPK2 in cancer 
A couple of studies focus on the amplification of HIPK2 in cancer and its loss of tumour 
suppressor function. Two independent high-resolution genome-wide array platform 
analyses could identify an amplification of the BRAF and HIPK2 encoding locus at 
7q34 in WHO Grade I pilocytic astrocytoma (PAs) [126]. Even though BRAF amplifica-
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tions and rearrangements (KIAA1549-BRAF fusion gene) represent the most common 
alterations in PAs, an examination of 42 tumours with BRAF alterations showed that 22 
out of 42 also featured HIPK2 amplifications [127]. Additionally, clonogenic assays with 
U87 GBM cells demonstrated that HIPK2 overexpression lead to increased cell growth 
in vitro [126]. 
Also, HIPK2 mRNA and protein levels increase in cervical cancer in comparison with 
normal cervical tissues, indicating a role in the development of the tumour. However, 
after the knockdown of HIPK2 in cervical cancer, tumour cells started to proliferate 
[128]. 
1.2.5 Role of HIPK2 in non-tumourigenic diseases 
Recent findings indicate a role of HIPK2 in non-tumourigenic diseases: kidney injury, 
kidney fibrosis, human immunodeficiency virus associated nephropathy, focal segmen-
tal glomerulosclerosis, diabetic nephropathy and IgA nephropathy. HIPK2 has been 
shown to be a key regulator of kidney fibrosis and upregulated in all of these kidney 
diseases. Depletion of HIPK2 in transgenic mice model improves their renal function 
[129, 130].  
Besides kidney fibrosis, there is evidence that HIPK2 influences the pathogenesis of 
human idiopathic pulmonary fibrosis (IPF). Fibroblasts of patients suffering from IPF 
exhibit low HIPK2 levels due to the HIPK2 loss of heterozygosity at locus 7q34 [131]. 
Since the conformational state of p53 is related to Alzheimer's disease (AD), a connec-
tion with its activator HIPK2 has been proposed. The deposition of beta-amyloid pep-
tides is the result of an amyloidogenic pathway in AD, and there is evidence that solu-
ble beta-amyloid peptides can induce HIPK2 degradation [132, 133]. 
1.2.6 Mechanisms regulating HIPK2  
HIPK2 activity can be regulated by its cellular localization. In unstressed cells HIPK2 
resides mainly in nucleoplasm. Upon severe DNA damage due to drugs (Cisplatin, 
Etoposide, Adriamycin), radiation (UV, IR) or replicative stress HIPK2 is recruited to 
PML nuclear bodies, where it colocalizes with p53 and phosphorylates p53 at Ser46, 
thereby regulating its acetylation [99].  
Apart from cellular mislocalization, HIPK2 is permanently degraded by different ubiqui-
tin E3 ligases such as Siah-1, Siah-2, WSB1, MDM2, and SCFFbx3 in order to restrict its 
abundance [106, 134-137]. Upon DNA damage, HIPK2 is activated by the checkpoint 
kinase ATM and ATR through inhibition of Siah-1, resulting in disruptions of HIPK2 and 
Siah-1, which, in turn, leads to stabilization of HIPK2 [135]. The HIPK2 pro-apoptotic 
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activity is also downregulated through a negative feedback loop, where p53 activates 
MDM2 and eventually degrades HIPK2 in case of non-lethal DNA damage [106].  
 
 
 
 
 
 
Hypoxic stress activates Siah-2, which in turn leads to proteasomal degradation of 
HIPK2. Since HIPK2 inhibits HIF-1α, the loss of HIPK2 results in HIF-1α stabilization 
and the expression of a hypoxic phenotype [137]. One way to restore the hypoxia-
inhibited HIPK2 pathway is zinc treatment, which promotes the proteasomal degrada-
tion of HIF1α [138]. 
Recently, an autoinhibitory loop has been identified, where the ATM/AMPKα2 pathway 
is activated upon ionic radiation, which leads to inhibition of HIPK2 and consequently a 
disinhibition leading to activation of WIP1. The stabilization of WIP1 eventually termi-
nates the double-strand break signalling cascades by inhibiting ATM [139]. 
1.3 Aim of this study 
Glioblastoma multiforme is still the most common and lethal brain tumour in adults. 
Although alterations of HIPK2 were already described in pilocytic astrocytoma, less is 
Figure 1.4: Regulation mechanisms of HIPK2. Chemotherapeutic drugs, radiation, or replica-
tive stress can lead to severe DNA damage and activation of HIPK2, which activates p53-
dependent and independent pathways in order to induce apoptosis. In unstressed cells HIPK2 is 
permanently degraded by its Ubiquitin-E3 ligases and also inactivated by its cytoplasmatic locali-
zation. Moreover, hypoxic conditions, viral proteins, such as HPV23 E6, or genetic aberrations 
can be the reason for altered HIPK2 stability or activity. Since Zinc downregulates HIF1-α, it is 
able to rescue the downregulated HIPK2. 
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known about changes in GBM. The aim of this study was to determine HIPK2 protein 
and mRNA expression, HIPK2 stability and the mRNA exon structures. Moreover SNP 
experiments were planned to identify amplifications of the HIPK2 locus and knockdown 
experiments in order to examine the role of HIPK2 in tumour proliferation. Since multi-
dimensional and comprehensive characterization studies revealed several mutations of 
HIPK2 in GBM, the idea came up to investigate its effects on phosphorylation, enzy-
matic activity, SUMO1- and PIN1 binding abilities and subcellular localization. A deeper 
understanding of the molecular mechanisms of HIPK2 in GBM should provide the basis 
for better tools in diagnosis or therapy of GBM. 
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2 Materials 
2.1 Cells 
2.1.1 Human glioblastoma cell lines 
Name Description (p53-status, 7q34-Amplification) 
A172 ♂ wt-p53 or Mut-p53 (Cys242Phe)* [1] 
U343 wt-p53 [2] 
U87 ♂ wt-p53 [1], 7q34+ [3] 
U118 ♂ Mut-p53 (Arg213Gln)* [1, 3] 
U251MG ♂ Mut-p53 (Arg273His)* [1] 
SNB19 Mut-p53 (Arg273His)* [1] 
Ln229 ♀ Mut-p53 (Lys164Glu)* [1] 
U373MG (Upsala) Mut-p53 (Arg273His)* [4], 7q34+ [3] 
A764  not known 
A271 not known 
G55 not known 
* cell lines with missense or small frameshift mutations 
2.1.2 Human non-glioblastoma cell lines 
Name Description 
HeLa ♀ Cervix carcinoma 
HEK-293T Embryonic kidney cells with large T antigen of SV40 virus 
U2OS ♀ Osteosarcoma 
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2.1.3 Competent E.coli strains 
Name Genotype Source 
TOP10 F-mcrA∆(mrr-hsdRMS-mcrBC)φ80lacZ∆M15 
∆lacX74 recA1 araD139 ∆(araleu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
2.2 Buffers 
 
Nonidet P40 lysis buffer (NP40): 
20 mM Tris/HCl (pH 7.5) 
1% (v/v) NP40  
10% (v/v) Glycerol  
150 mM NaCl 
prior to use: 
2 mM Na Vanadate 
40 mM NaF 
a drop PMSF 
5x SDS loading buffer: 
312.5 mM Tris/HCl (pH 6.8) 
50% Glycerol 
10% (w/v) SDS 
25% (v/v) β-mercaptoethanol 
0.01% (w/v) bromphenol blue 
  
4x Separating gel buffer (lower): 
1.5 M Tris/HCl (pH 8.8) 
0,4% (w/v) SDS 
4x Stacking gel buffer (upper): 
0.5 M Tris/HCl (pH 6.8) 
0,4% (w/v) SDS 
The preparation of the SDS gels is described in 3.2.2 
 
50x Tris-acetate-EDTA buffer (TAE): 
0.05 M EDTA 
2 M Tris (pH 8.3) 
1 M Acetic acid 
10x SDS running buffer: 
250 mM Tris 
2 M Glycine 
1% (w/v) SDS 
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Transfer buffer: 
50 mM Tris/HCl 
40 mM Glycine 
20% (v/v) Methanol  
0.038% (w/v) SDS   
Washing buffer (10x TBS-T): 
250 mM Tris 
1.37 mM NaCl 
50 mM KCl 
7 mM CaCl2 
1 mM MgCl2  
0.1% (v/v) Tween 20 
pH = 7.4 
  
Phosphate buffer saline (1x PBS): 
137 mM NaCl 
8.1 mM Na2HPO4 
2.7 mM KCl 
1.5 mM KH2PO4 
pH = 7.4 
Mini preparation buffer 1 (P1): 
50 mM Tris 
81 mM Na2EDTA 
10% RNase 
pH = 8.0 
  
Mini preparation buffer 2 (P2): 
200 mM NaOH 
20% 173 mM SDS (w/v) 
Mini preparation buffer 3 (P3): 
3 M Potassium acetate 
pH = 5.5 (with glacial acetic acid) 
  
GSH elution buffer: Dialysis buffer: 
100 mM Tris 20 mM Tris 
15 mM glutathione pH = 7.5 
pH = 8.0 
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2.2.1 Stock solutions 
 
 
2.2.2 Medium compositions 
 
Name Description 
Dulbecco’s Modified Eagle Medium (DMEM) From Gibco®  by Life technologies 
Luria Bertani Medium (LB) 1% (w/v) Tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
If needed, appropriate antibiotics 
were added. 
Luria Bertani Agar Plates 1% (w/v) Tryptone 
0.5 % (w/v) yeast extract 
1% (w/v) NaCl 
1.6% (w/v) Agar 
Appropriate antibiotics were added. 
Name Composition 
Complete Medium DMEM containing 2 mM Glutamine, 10% (v/v) FCS and 
1% (v/v) Penicillin/Streptomycin 
Transfection Medium 1 DMEM containing 2 mM Glutamine 
Transfection Medium 2 DMEM containing 2 mM Glutamine and 10% (v/v) FCS 
Freezing Medium FCS containing 10% (v/v) DMSO 
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2.3 Chemicals 
2.3.1 Enzymes 
 
2.3.2 Inhibitors 
 
 
Name Source 
DNase I Qiagen 
GoTaq®-Polymerase  Promega 
Lysozyme Sigma 
Pfu Ultra DNA Polymerase Stratagene 
Restriction endonucleases Thermo Scientific 
Super Script II reverse transcriptase Invitrogen 
Trypsin-EDTA Gibco® by Life technologies 
Name Targets Source 
Aprotinin Serine proteases Sigma 
Leupeptine Serine and cysteine proteases Sigma 
Phenylmethylesulfonyl  
fluoride (PMSF) 
Proteases Sigma 
RiboLock R1 RNAse Thermo 
Scientific 
Sodium fluoride (NaF) Serine- and threonine phosphatases Roth 
Sodium orthovanadate (Na3VO4) Tyrosine- and alkaline phosphatases Sigma 
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2.3.3 Antibiotics 
 
Name Final concentration Source 
Ampicillin  100 µg/ml Sigma 
Cycloheximide  10 µg/ml Sigma 
Penicillin/Streptomycin  10000 U/ml Gibco 
Puromycin  1-2 µg/ml Invitrogen 
 
2.3.4 Kits 
 
Name Company 
ABsolute qPCR SYBR Green ROX Mix Thermo Scientific 
JETstar Plasmid Purification Maxi Kit Genomed 
Pierce® BCA Protein Assay Kit Thermo Scientific 
QuikChange® Site-Directed Mutagenesis Kit Agilent 
RNeasy® Mini Kit Qiagen 
 
2.3.5 Other chemicals 
 
Name Source 
(L-)Glutamine Gibco 
1,4-Dithiothreitol (DTT) Acros Organics 
2-Propanole Roth 
2-β-Mercaptoethanol Roth 
5x GoTaq Flexi buffer Promega 
5x Green GoTaq Flexi Buffer Promega 
Acetone Roth 
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Agarose PeqLab 
Ammonium persulfate (APS) Sigma 
Bovine serum albumine Sigma 
Buffer RDD DNA Digestion buffer Qiagen 
Desoxyribonucleosidetriphosphates (dNTPs) Thermo 
Dimethylsulfoxide (DMSO) Sigma 
Enhanced chemiluminescence solutions (ECL)  Perkin Elmer 
Ethanol Roth 
Ethidiumbromide Roth 
FACS Clean BD Bioscience 
FACS Flow BD Bioscience 
FACS Rinse BD Bioscience 
Fetal Bovine Serum (FCS) Gibco by Life technologies 
Glycin Roth 
Goat serum Sigma 
GST V. V. Saul 
GST-PIN1 M. Milanovic 
GST-SUMO V. V. Saul 
Hoechst (33342) Invitrogen 
Hydrogen chloride (HCl) Roth 
IPTG Roth 
Kaiser’s Glyceringelatine Merck 
Magnesium chloride (MgCl2) Promega 
Methanol Roth 
Microscope Slides Thermo Scientific 
Milk powder Merck 
NaCl Roth 
Oligo (dT)12-18 Primer Invitrogen 
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Polybrene (Hexadimethrin Bromid) Sigma 
Polyethyleneimine (PEI) Sigma Aldrich 
Potassium acetate Roth 
Protein A/G  agarose beads Santa Cruz Biotech 
RNase A Sigma 
RNAse-Free Water Promega 
Roti®-Fect Roth 
Sodium azide (NaN3) Roth 
Sodium dodecyl sulfate (SDS) Bio Rad 
Sodium hydroxide (NaOH) Roth 
Tetramethylethylenediamine (TEMED) Bio Rad 
Tris Roth 
Tween 20 Roth 
Water MilliQ 
 
2.4 Antibodies 
2.4.1 Primary Antibodies 
 
Name (clone) Species Origin Source 
anti-Flag (M2) mouse  monoclonal Sigma 
anti-GFP (7.1 and 13.1) mouse  monoclonal Roche 
anti-HIPK2 (rab) rabbit  polyclonal M.L. Schmitz 
anti-HIPK2 (C1B3) rat monoclonal M.L. Schmitz 
anti-HIPK2 (5C6) rat  monoclonal M.L. Schmitz 
anti-HIPK2 (N6A10) rat  monoclonal M.L. Schmitz 
anti-Ubiquitin (P4D1) mouse  monoclonal Cell Signaling 
anti-β-Actin rabbit  polyclonal Abcam 
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anti-β-Tubulin (Tub2.1) mouse  monoclonal Sigma 
 
2.4.2 Secondary Antibodies 
 
Name Species Conjugated to Source 
anti-mouse IgG (GAM) Goat Horseradish 
peroxidase 
Dianova 
anti-mouse-488 IgG (GAM-488) Goat Cy3 Dianova 
anti-rabbit IgG (GAR) Goat Horseradish 
peroxidase 
Dianova 
anti-rat IgG (GARat) Goat Horseradish 
peroxidase 
Dianova 
 
2.5 Oligonucleotides 
All Oligonucleotides were ordered from Sigma. 
2.5.1 Oligonucleotides for PCR 
 
Name Sequence (5’ à  3’) Species 
HIPK2 Exon1 for CCCGTGTACGAAGGTATGGC human 
HIPK2 Exon1 rev TGGCAGTGGCGACAGTGG human 
HIPK2 Exon2 rev CTGCAAGTAGGTGGAGCACA human 
HIPK2 Exon8 for TTGTACCTCTAGACGTTCG human 
HIPK2 Exon8 rev CCTCTAAGCACGCTGGCTA human 
HIPK2 Exon12 for CGGTCAGCGTCATCACCAT human 
HIPK2 Exon12 rev AGCACGCTGCTGCACGGAGT human 
HIPK2 Exon14/15 for2 GATGAGGCACGTCGTCGCA human 
HIPK2 Exon14/15 rev3 CAAGTTTCACTGGTGTCCCGA human 
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HIPK2 Exon 2 rat rev TTGCAAGTACGTAGAACAGAC rat 
 
2.5.2 Oligonucleotides for Real-Time PCR 
 
Name Sequence (5’ à  3’) Species 
HIPK2 qRT N-term Primer3 for CCTACCTTACGAGCAGACCAT human 
HIPK2 qRT N-term Primer3 rev  CTTGCCCGGTGACAGAAGT human 
HIPK2 qRT C-term for CCATCCACCCGAGTCAGTAT human 
HIPK2 qRT C-term rev AGGGTACTGGTTGACCTTGG human 
 
2.5.3 Oligonucleotides for site-directed Mutagenesis 
 
Name Sequence (5’ à  3’) 
HIPK2 R404W for TCGGAGTATGATCAGATTTGGTATATTTCACAAACACAGG 
HIPK2 R404W rev GTGTTTGTGAAATATACCAAATCTGATCATACTCCGAAGC 
HIPK2 R826C for CACAGCGATCCAAGTGTGTCAAGGAGAACACACC 
HIPK2 R826C rev GTGTTCTCCTTGACACACTTGGATCGCTGTGGG 
HIPK2 E890G for CACGGACGAGGGGGAGGAACAGAAACACG 
HIPK2 E890G rev GTTTCTGTTCCTCCCCCTCGTCCGTGTC 
HIPK2 E891K for CGACGAGGAGAAGGAACAGAAACACGCC 
HIPK2 E891K rev CGTGTTTCTGTTCCTTCTCCTCGTCCGTG 
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2.6 Plasmids 
 
Name Vector Epitope tag Source 
HIPK2 wt pcDNA3 Flag L. de la Vega 
HIPK2 Mut1 pcDNA3 Flag L. de la Vega 
HIPK2 Mut2 pcDNA3 Flag L. de la Vega 
HIPK2 ∆SIM pcDNA3 Flag L. de la Vega 
HIPK2 K221A pcDNA3 Flag L. de la Vega 
HIPK2 R404W pcDNA3 Flag D. Darici 
HIPK2 R826C pcDNA3 Flag D. Darici 
HIPK2 E890G pcDNA3 Flag D. Darici 
HIPK2 E891K pcDNA3 Flag D. Darici 
pPAX2 - - Addgene 
pMD2.G - - Addgene 
MEF2D - Flag V.V. Saul 
shHIPK2 #5 pLKO.1 - Sigma 
shHIPK2 #4 pLKO.1 - Sigma 
shScramble pLKO.1 - Sigma 
GFP pLKO.1 Flag AG Bindereif 
SUMO1 pGEX GST V.V. Saul 
PIN1 pGEX GST M. Milanovic 
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3 Methods 
3.1 Methods in cell biology 
3.1.1 Cell culture 
3.1.1.1 Harvesting and subcultivation 
Adherent cells were grown in complete DMEM Medium in a humidified incubator at  
37°C and 5% CO2. The confluence was determined daily by light microscopy.  
When cells reached 80% confluency they were trypsinized by adding Trypsin/EDTA (3 
ml at 75 cm flask and 5 ml at 175 cm flask) and incubated for 5 min at 37°C. After add-
ing 3 ml of complete DMEM medium the cells were transferred in a new flask (1:10 or 
1:20 dilution – depending on cell growth). 
3.1.1.2 Freezing and thawing 
For freezing purposes, cells were trypsinized as described in 3.1.1.1 and resuspended 
in complete DMEM medium. After centrifugation at 400 g for 3 minutes, the superna-
tant was discarded, the pellet was resuspended with 1 ml freezing medium and the 
suspension was pipetted in a cryotube. The cryotubes then were carefully cooled down 
in a plastic rack slowly to -80°C and after two days transferred to a -150°C freezer. 
For thawing purposes, the freezing medium - containing cytotoxic DMSO – needs to be 
discarded. Therefore the cell-suspension was quickly thawed at 37°C, transferred to a 
falcon containing 10 ml of complete DMEM medium and centrifuged at 400 g for 3 min. 
After removal of the supernatant, cells were resuspended with complete DMEM medi-
um and put in a new flask. 
3.1.2 Transfection 
3.1.2.1 Transfection with cationic polymers 
This method was used to introduce DNA into HEK-293T cells that are easy to transfect. 
It is based on the binding of the cationic polymers to the negatively charged DNA and 
the cellular uptake via endocytosis.  
A 6 cm dish with 293T cells was seeded one day before transfection. For each mi-
crogram of DNA 2 µl of Polyethylenimine (PEI) volume was used and mixed with 
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Transfection Medium 1. The transfection mix was incubated for 20 min at room tem-
perature. Meanwhile the complete DMEM medium on the cells was removed and 
changed to antibiotic-free Transfection Medium 2. The transfection mix was then ap-
plied to the cells and incubated at 37°C. After 4-6 h the medium was changed to com-
plete DMEM medium. Cells were analyzed 2 days after transfection. 
3.1.2.2 Transfection with lentivirus 
Lentiviral transfection was used to introduce DNA into glioblastoma cells, which exhib-
ited low transfection-efficiency, especially for knockdown experiments. This method is 
divided into two steps. First step is to produce the lentivirus, the second step is to infect 
the cells with the lentivirus. Due to risk of infection, all steps were performed under bi-
osafety level 2 conditions.  
3.1.2.2.1 Production of the lentivirus 
In order to produce the lentivirus HEK-293T cells were seeded in 10 cm dishes and 
transiently transfected the following day with 5 µg of PAX 2,5 µg of pMD2.G and 5 µg 
of the knockdown vectors using Roti®-Fect. For each microgram of DNA 2 µl of Roti®-
Fect was used and mixed with Transfection Medium 1. The transfection mix was incu-
bated for 20 min at room temperature. Meanwhile the complete DMEM medium on the 
cells was removed and changed to antibiotic-free Transfection Medium 2. After incubat-
ing the transfection mix for 4-6 h, 5 ml of complete DMEM was applied to the cells. Two 
days later the supernatant, containing the virus particles, was extracted. It was centri-
fuged at 400 g for 2 min and filtered through a 0.45 µm filter to remove remaining HEK-
293T cells. If needed lentiviruses were frozen at -80°C for later use. 
3.1.2.2.2 Lentiviral infection of the cells 
Lentiviral infection of the cells was done by applying a certain amount of infectious len-
tiviral medium and 10 µg of Polybrene to the cells. The optimum virus titer was deter-
mined by infecting U87MG and A172 cells with different volumes of infectious medium 
over 8 days, where 500 µl turned out to work best. Infection efficiency was checked by 
lentiviral transfection of a GFP-encoding virus under the fluorescence microscope. 
3.1.3 Lysis 
3.1.3.1 NP40-Lysis 
Lysis with the nonionic detergent NP40- was found to be suitable to extract the endog-
enous HIPK2 protein. All steps were performed on ice. At first the medium was re-
moved from the cells. Subsequently the cells were washed 2 times with appropriate 
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volumes of cold PBS to remove remaining medium. Then the cells were scraped off 
and collected in a tube. Depending on the size of the pellet, different volumes of NP40-
Lysis Buffer (premixed with inhibitors) were added and thoroughly resuspended. After 
20 minutes lysis on ice – including several vortexing steps intermittently – a centrifuga-
tion step for 12 min at 13000 rpm was performed. The supernatant was extracted and 
either directly used for protein quantification assays or mixed with SDS buffer at final 
concentration of 1x, followed by a 5 min heating step at 95°C for protein denaturation. If 
needed, samples were frozen at -80°C for later use. 
Prior to use, following protease-inhibitors were freshly added to the lysis buffer: 
 
 Aprotinin Leupeptin Na3Va4 NaF PMSF 
Final Concentration 10 µg/ml 10 µg/ml 0.5 mM 10 mM < 1 mM 
 
3.1.3.2 SDS-Lysis 
Denaturing SDS-Lysis was performed to solubilize nuclear proteins. All steps were per-
formed on ice. After removing the medium and two washing steps with appropriate vol-
umes of cold PBS the cells were collected in a tube and directly mixed with 1x SDS 
sample buffer.. The lysate was sonified two times for 20 sec and heated at 95°C for 5 
min. If needed, samples were frozen at -80°C for later use. 
3.1.4 Immunofluorescence 
Immunofluorescence experiments were usually performed with U2OS osteosarcoma 
cells seeded on glass coverslips in 12-well plates., At a confluence of 80%, cells were 
transiently transfected with 1 µg of DNA. Two days after transfection cells were fixed 
on the cover glasses by adding 1 ml of a -20°C cold acetone/methanol-mixture for 1 
minute. Unspecific binding-sites were blocked by using 1 ml of a blocking buffer con-
taining 10% goat-serum in PBS for 60 min. Following steps are describing the detection 
with the antibodies which were diluted in PBS containing 1% (v/v) goat-serum. 
The anti-Flag [M2] antibody was diluted (1:4000), whereof 500 µl was applied and in-
cubated at 4°C over night. Because of light sensitivity, following steps were performed 
under a light-protecting box. Four washing steps with PBS were performed.  
The next day, cells were treated with the secondary antibody anti-mouse (dilution 
1:5000). After an incubation of 2 h, the cells were washed two times with PBS and  
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stained with Hoechst (1:10000) dye for 8 min in order to reveal the cell nucleus. The 
coverslips were mounted up site down on the slide with a drop of mounting solution 
and incubated at -4°C for 1 h. Finally nail polish was used to secure and prevent the 
coverslips from moving and drying out. 
3.1.5 Proliferation assays with Flow cytometry (FACS) 
FACS analysis was used to determine the cell number for proliferation assays upon 
HIPK2 knockdown. The GBM cells were transduced with lentiviruses to express a 
HIPK2-specific shRNA.  
Since the lentiviral transfection experiment terms were established for 6-well-plates, 
GBM cells were seeded on two 6-well-plates. The lentiviruses were produced as de-
scribed in 3.1.2.2.1 with the vectors shHIPK2#5 and shScramble. After the extraction of 
the virus particles, one plate was infected with lentiviruses containing shHIPK2#5 and 
the other plate with shScramble (as described in 3.1.2.2.2). Puromycin selection with 4-
10 µg (depending on cell line) was performed to eliminate the non-transfected cells. 
One day after selection, cells were pooled and counted via FACS. 2 * 105 cells were 
seeded on 6 cm plates each, which in pretests seemed to work best. Experiments were 
done in duplicates over 6 days and cells were counted by FACSCalibur after 2, 4 and 6 
days. 
The counting of the cells was performed for 120 sec at low flow rate (12 µl/min) under 
following settings: 
Parameter Detector Voltage Amp Gain Mode 
P1 FSC E00 1,00 lin 
P2 SSC 300-400 1,00 lin 
P3 FL1 394  log 
P4 FL2 340  log 
P5 FL3 200  log 
 
3.2 Methods in biochemistry 
3.2.1 Bicinchoninic acid (BCA) assay 
The BCA assay is a method to quantify the total level of proteins and was used to de-
termine protein amounts after NP40-Lysis (3.1.3.1) so that equal amounts of protein 
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could be used for SDS-PAGE (3.2.2). Using the PierceTM BCA Protein Assay Kit, 150 µl 
of the Working Reagent (50:1, Reagent A:B) was mixed with 10 or 20% of the lysate 
and incubated for 30 min at 37°C. Absorbance was then measured at 562 nm in a 96-
well-plate Spectrophotometer, normalized to water and total protein amount was de-
termined comparing with a BSA-standard curve. 
3.2.2 SDS-Polyacrylamid gel electrophoresis (SDS-PAGE) 
First step in the detection of proteins is the SDS-PAGE, which separates polypeptides 
based on their size independently from their charge. For this purpose, SDS-gels have 
been prepared in different concentrations - depending on the protein size of interest - 
as follows: 
Separating gel [1.5 mm]: 
% Acrylamid 6% 8% 10% 12% 
30% Acrylamid 1,6 ml 2,1 ml 2,7 ml 3,2 ml 
4x Lower Buffer 2 ml 2 ml 2 ml 2 ml 
ddH2O 4,4 ml 3,9 ml 3,3 ml 2,8 ml 
10% APS 50 µl 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 5 µl 
 
Stacking gel [1.5 mm]: 
30% Acrylamid 0,5 ml 
4x Lower Buffer 1 ml 
ddH2O 2,5 ml 
10% APS 50 µl 
TEMED 5 µl 
If needed, gels were stored in a humidified plastic bag for at least two days in a fridge. 
All samples were loaded on the gel with the Hamilton pipette. The protein marker was 
loaded in the first lane and the lysates beside. Empty lanes were filled up with 1x SDS 
buffer to avoid bendings. The whole gelelectrophoresis chamber is divided into two 
disconnected chambers, where the inner chamber, locating the samples, was filled with 
new fresh Running buffer and the outer chamber with old Running buffer in order to 
save resources. Migration of the proteins was achieved by applicating voltage from a 
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power supply. 80 V were supplied until the samples entered the stacking gel. Further 
electrophoresis was performed with 100 V for about up to 3 h. 
3.2.3 Western blot and immune detection 
After SDS-Page, the gel was blotted to a PVDF membrane using the method of semi-
dry protein transfer. First step was to prewet the PVDF membrane with 100% methanol 
to reduce its hydrophobicity. Next step was to construct a blotting Sandwich, bottom-up 
consisting of two layers of soaked Whatman papers, the PVDF membrane, the gel and 
one layer of Whatman paper on the top. Soaking was performed in Transfer buffer by 
paying attention, that the chamber is not completely floated. Potential air bubbles were 
removed by rolling with Falcon. Depending on the protein size, 24 V were applied con-
stantly for at least 1 h. Bigger proteins, such as HIPK2 (~130 kDa) were blotted for 2 h. 
After the blotting the PVDF membrane was incubated for 30 min in TBS-T with 10% 
milk powder at room temperature.  
Immune detection was performed by incubating the blocked membrane with the pro-
tein-specific first antibody over night at 4 °C. The next morning, after five washing steps 
with TBS-T for 3 min each, the Horseraddish-peroxidase-conjugated second antibody, 
which is detecting the first antibody, was added and incubated for 1 h at room tempera-
ture followed by a second washing procedure. Subsequently the antibody-coupled 
membrane was soaked with an enhanced chemiluminescence lightning (ECL) system, 
which is reacting with the Horseraddish peroxidase (HRP) by producing chemilumines-
cence at 425 nm. 
Under light-protective conditions, the chemiluminescence was detected with an X-ray 
film and visualized with an automated X-ray film developer. 
3.2.4 Expression and purification of GST fusion proteins 
GST fusion proteins were expressed and purified to perform GST-pulldown experi-
ments (3.2.5). First, competent BL-21 E.coli cells were transformed with GST vectors 
including GST only as a positive control. 2 colonies of each clone was inoculated in 2 
ml of LB-amp. After growing over night at 37°C, 8 ml of warm LB-amp was mixed with 
the cells and grown for 30 min on the shaker. The cultures were split equally in 2 tubes. 
5 µl of IPTG (1 M) was added to one colony in order to induce protein expression. The 
cells were cultured for 120 min at 30°C and collected by centrifugation (3000 g for 10 
min at 4°C). The pellet was washed with 300 µl of cold PBS and the pellet was dis-
solved. 50 µl of Lysozyme solution (10 mg/ml) was added and incubated for 20 min on 
ice. The samples were additionally sonified four times for 20 sec and centrifuged for 15 
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min at 26 000 g at 4°C. The supernatant was transferred to a new Eppendorf tube, 25 
µl of equilibrated glutathione (GSH) sepharose beads was added and incubated for 1 h 
on a spinning wheel. Four washing steps with 10 ml cold PBS were performed. Bound 
GST fusion proteins were eluted by resuspending the beads in 500 µl GSH elution 
buffer. Eluates were pooled and dialyzed in 1 L dialysis buffer overnight at 4°C. Finally 
a SDS-Page was performed to quantify the purified GST fusion proteins. 
3.2.5 GST pull-down assay 
GST pull-down assay is an in vitro method used to determine physical interaction be-
tween proteins. HEK-293T cells were seeded on 10 cm plates and transiently trans-
fected with HIPK2 vectors in order to express and analyze different mutants of the pro-
tein. One day after transfection, cells were lyzed using NP40-lysis (3.1.3.1). 5 % of the 
lysates were used as an input control, whereas the remaining lysates were divided 
equally and incubated with either 5 µg of the non-fused GST protein or 5 µg of the GST 
fusion protein together with 50 µg GSH sepharose each for 4 h at 4°C on a rotating 
wheel. After centrifugation at 2000 g for 1 min, the supernatant was discarded and the 
pellet was washed three times with NP40-buffer. The elution of the binding proteins 
was achieved by mixing 100 µl of 2 x SDS sample buffer, heating it for 4 min and ana-
lyzing by Western blot (3.2.3). 
3.3 Methods in molecular biology 
3.3.1 Total RNA extraction 
The extraction of total RNA from cell culture tissue was performed with the RNeasy 
Mini kit using column technology by following the official protocol with few modifica-
tions. Because of RNA instability and RNases, work was performed quickly on a 
cleaned bench. All centrifugation steps were done at 13200 rpm. Cells were harvested 
(3.1.1.1) preferentially from 10 cm plates to increase the RNA yield. Cells were washed 
two times with PBS. 1 ml of RLT lysis buffer was premixed with 10 µl β-
Mercaptoethanol in order to irreversibly denauture RNases by reducing its disulfide 
bonds. To homogenize the lysate, cells were passed through a RNase-free syringe for 
around 3 minutes. 1 ml of 70%-Ethanol was then added to the homogenized lysate. 
700 µl of the sample was loaded on a column. Centrifugation was performed for 1 mi-
nute and the flow-through was discarded. These steps were repeated until all suspen-
sion was lost. Next 350 µl of RWE1 buffer was added to the spin column and centrifu-
gated for 30 sec. Afterwards a DNase-mix, containing  
60 µl RDD buffer and 10 µl DNase I, was put on the column and incubated for 15 min. 
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After DNase-treatment, two independent cleaning steps with 350 µl of RWE1 buffer 
and 700 µl RPE buffer were performed. Last step included a dilution of total RNA from 
the column, which was achieved by adding appropriate volumes of RNase-free water – 
the volume was depending on the yield, which was varying between cell-lines. To avoid 
subsequent RNA degradation, 1 U of the RNase inhibitor Ribolock was pipetted to the 
RNA-elution. To measure RNA yield and quality, 1 µl of elution was mixed with 70 µl 
RNase-free water and photometrically measured. Quality (absorption at 260/280) of the 
RNA was between 1.8 and 2.0 in average. If needed RNA was frozen at -80°C for later 
use. 
3.3.2 cDNA synthesis 
Reverse transcription is the method to transform mRNA into cDNA. One µg of total 
RNA was mixed with 1 µl of Oligo-dT12-18-Primer and 1 µl of dNTPs which then was 
adjusted to a total volume of 12 µl with water and heated at 65°C for 5 min. After add-
ing 2 µl of 0,1M DTT and 4 µl of 5x First-strand buffer, the solution was heated again at 
42°C for 2 min. Finally 1 µl (200 units) of the reverse transcriptase enzyme (Super-
Script II RT) was added, resuspended properly and the reaction mix was incubated for 
55 minutes at 42°C and for 15 min at 70°C. If needed, cDNA was frozen at 20°C for 
later use. 
3.3.3 Polymerase chain reaction (PCR) 
PCR, as a powerful method to simply amplify specific nucleotide regions of interest, 
can be performed for many different purposes. Since a couple of primers were used for 
the reactions, all reactions had to be optimized by pretests.  
These pretests were done with varying concentrations of Mg2+, primers and cDNA tem-
plates and with different annealing temperatures. For sequencing purposes, the reac-
tion volume was doubled. 
 Exon analysis Sequencing 
5x Green Buffer 5 µl 10 µl 
dNTPs (10 mM) 0,5 µl 1 µl 
Forward Primer (5 µM) 2,5 µl 5 µl 
Reverse Primer (5 µM) 2,5 µl  5 µl 
MgCl2 (25 mM) 3 µl 6 µl  
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The reagents were mixed properly on an ice rack, whereas the Taq-Polymerase was 
added right before putting it in the Biorad cycler.  
 
 Temperature Time Number of cycles 
Initial Denauturation 95°C 3 min 1 cycle 
Denauturation 95°C 30 sec  
35x Annealing 57-67°C 30 sec 
Elongation 72°C 1 min/kb 
Final elongation 72°C 5 min 1 cycle 
Storage 10°C infinite hold  
Furthermore the product of the reaction could be either digested with restriction en-
zymes (3.3.4) visualized by agarose gel electrophoresis (3.3.7), purified for sequencing 
(3.3.8 and 3.3.9) or frozen at -20°C for later use. 
3.3.4 DNA digestion with restriction endonucleases 
Bacterial restriction endonucleases are able to cut palindromic DNA sequences at spe-
cific restriction sites. They were usually used to control PCR products, after isolation of 
plasmid DNA (3.3.11) and after site-directed mutagenesis (3.3.5). 
The following table illustrates the composition of the reaction mix: 
 
Reagent Volume 
Plasmid DNA (1 µg/µl) 2 µl 
10 x restriction buffer 2 µl 
Restriction enzyme (10 U/µl) 0,1 µl 
ddH2O 10,9 µl 
Taq-Polymerase 0,15 µl 0,3 µl 
DMSO (50% in H2O) 2,5 µl 5 µl 
cDNA (20 ng) 2,5 µl 5 µl 
ddH2O 6,35 µl 12,7 µl 
total 25 µl 50 µl 
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The mix was incubated at 37°C for 2 h and analyzed by agarose gel electrophoresis 
(3.3.7). 
3.3.5 Site-directed mutagenesis  
Site-directed mutagenesis is a method to modify the primary DNA code by changing, 
inserting or deleting bases. Basically several primers, which contain the desired muta-
tion, were constructed.  
The mutagenesis reaction was performed using the Quick-Change-Mutagenesis Kit. 
Following reagents were mixed on an ice rack: 
 Volume 
Plasmid DNA (100 ng/µl) 1 µl 
10x Reaction Buffer 5 µl 
dNTP mix (10 mM) 1 µl 
Quik Solution 3 µl 
Pfu Polymerase (2,5 U/µl) 1 µl 
forward primer (10 µM) 1,3 µl 
reverse primer (10 µM) 1,3 µl 
ddH2O (MilliQ water) 36,4 µl 
Total volume 50 µl 
 
Afterwards the following PCR program was used for site-directed mutagenesis. 
 Temperature Time Number of cycles 
Initial Denauturation 95°C 1 min 1 cycle 
Denauturation 95°C 50 sec 18 cycles 
Annealing 57-60°C 50 sec 
Elongation 68°C 9 min 
Final elongation 68°C 5 min 1 cycle 
Storage 10°C Infinite  
After the PCR finished, DpnI, an enzyme which cleaves the parental methylated bacte-
rial template-DNA, was added and incubated for 2 h at 37°C. Subsequently an Agarose 
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gel electrophoresis (3.3.7) was performed and the specific band was purified using 
Agarose gel extraction (3.3.8). The purified Plasmid-DNA was transformed in bacteria 
(3.3.10) and several clones from the Agar-plate were picked, enriched in mini-
preparations (3.3.11) and sequenced (3.3.9) for screening purposes. If a clone was 
positive for the mutation, a maxi-preparation (3.3.11) was done and the products were 
test expressed in HEK-293T cells. Correct expression of the mutated protein was en-
sured by SDS-PAGE (3.2.2) and Western blotting (3.2.3). 
3.3.6 Real-Time Quantitative PCR (qPCR) 
The RT-PCR enables monitoring of DNA-quality and quantity by measuring the DNA-
amount dependent increase of fluorescent-dyes during PCR. This was achieved by 
adding the DNA binding SYBR green to the PCR reaction. The method was basically 
used to analyze mRNA expression levels. For that purpose, cells were seeded on 10 
cm plates and total RNA was extracted (3.3.1). The mRNA was translated in cDNA 
(3.2.2). Several dilution-pretests were performed in order to determine the right con-
centration of the reagents, incuding DNA- and primer-concentration gradients. 
The qPCR was started mixing the following reagents on ice: 
 Volume 
cDNA (10 ng/µl) 2 µl 
ABsolute SYBR green ROX mix 5 µl 
forward primer (5 µM) 0,4 µl 
reverse primer (5 µM) 0,4 µl 
ddH2O 2,2 µl 
Total volume 10 µl 
Accordingly the qPCR was performed in triplicates in an ABI 3000 Real-time PCR cy-
cler (Applied Biosystems), using the following program: 
 
 Temperature Time Number of cycles 
Initial Denauturation 95°C 15 min 1 cycle 
Denauturation 95°C 15 sec  
40 cycles Annealing 60°C 30 sec 
Elongation 72°C 30 sec 
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The fluorescence was measured after the Elongation step and an additionally melting 
curve analysis was performed to evaluate the specificity of the amplified products. After 
normalizing the ct-values to the housekeeping gene β-actin, the relative expression 
was calculated using the comparative 2-∆∆ct method by comparing to a predefined ref-
erence transcript (expression = 1). 
3.3.7 Melting Curve Analysis 
Melting curve analysis is a method, which is able to detect dissociation-characteristics 
of dsDNA. After a Real-Time PCR experiment, a heating step is performed with in-
creasing temperatures by constantly measuring the fluorescence. Since SYBR Green® 
is sending fluorescence when bound to dsDNA, the dissociation of dsDNA upon heat-
ing into ssDNA decreases the signal. The dissociation properties of DNA are depend-
ing on the amount of base pairing while G-C rich DNA has a higher melting tempera-
ture than DNA with a higher A-T content. Melting Curve Analysis was performed in a 
Real-time PCR cycler (Applied Biosystems). 
3.3.8 Agarose gel electrophoresis 
Agarose gelelectrophoresis was mainly used to separate linear DNA, RNA and Plas-
mids by their size. Depending on the expected size, miscellaneous amounts of agarose 
was heated with 50 ml TAE buffer in the microwave until the particles completely dis-
solved. Afterwards 1 µl of Ethidiumbromide, an intercalating dye, was added to the 
suspension. The gel was poured in a chamber and a comb was inserted. The whole 
chamber was filled with TAE buffer and electrophoresis was performed at 80 V in the 
presence of an appropriate DNA marker. After electrophoresis a picture of the gel was 
taken under UV illumination, where the stained DNA bands appeared as glowing 
bands.  
Agarose gel extraction 
Agarose gel extraction is a method to purify DNA fragments from agarose gels. The 
band of interest was visualized under 70% UV-irradiation in order to limit DNA damage 
and cutted out with a proper scalpel. The following steps were performed as described 
in the protocol using the gel extraction kit from JetStar. 
3.3.9 Sequencing 
Sequencing was used to reveal unknown primary base structures of Plasmid-DNA. For 
this purpose, samples were prepared as follows: 
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 final concentration 
Plasmid DNA 80 ng/µl  
Primer 30 pmol/µl  
ddH2O ad 15 µl 
After premixing the substances, the mix was sent to SeqLab (Microsynth Company), 
who analyzed the samples over night and told the results via e-Mail. 
3.3.10 Competent E.coli transformation 
Transformation describes the uptake of exogenous DNA material from bacterial cells 
and is the first step of plasmid amplification. Therefore plasmid DNA was carefully 
mixed with 50 µl of chemically competent E.coli and incubated for 20 min on ice, follow-
ing a short heatshock for 90 sec at 42°C in order to allow DNA entering through cell 
pores. After incubating the bacteria for 5 minutes on ice, 500 µl of antibiotica-free LB 
medium was added and incubated at 37°C on a shaker for 1 h. Finally, successfully 
transformed cells were selected through plating on LB agar containing the appropriate 
antibiotic and incubated at 37°C for at least 12 h., 
3.3.11 Plasmid DNA purification 
After transformation (3.3.10), plasmid DNA of interest was purified using the column-
based Jetstar 2.0 Plasmid Mini/Midi/Maxi kit according to manufacturer's instructions. 
The kit uses a modified alkaline/SDS lysis procedure and a column, where the nega-
tively charged plasmid DNA is bound to the positive charges on the resin surface. Once 
the lysate ran through the column, several washing steps were performed to remove 
RNA, proteins and carbohydrates. Afterwards RNAse I was added to the column to 
remove further RNA impurities. The plasmid DNA was eluted and precipitated from the 
elute with isopropanol and 70% ethanol. A photometrically determined purity of the 
DNA around 1.80 (OD260/280) was achieved.  
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4 Results 
4.1 Analysis of HIPK2 in GBM 
4.1.1 Protein levels of HIPK2 in GBM 
Several studies described alterations in the serine-threonine kinase HIPK2 in cutane-
ous tumours [140], leukaemia [124] and other neoplasms [113, 141, 142]. In low-grade 
pilocytic astrocytoma (WHO I), in particular, there is evidence of a Hipk2 amplification 
on gene locus 7q34 [126, 127, 143]. These findings raise the question whether these 
alterations also occur in high-grade GBM (WHO IV). The first intention of this project 
was to determine the endogenous HIPK2 expression in 12 GBM cell lines and compare 
them to HIPK2 levels in other cell lines such as HeLa cells (cervix carcinoma) and 
HEK-293T cells (human embryonic kidney cells).  
To address these questions, semi-quantitative Western Blot experiments should be 
performed. Before performing the experiment, several pretests had to be conducted. 
The first point was to test if the antibodies are detecting HIPK2 confidently. Therefor a 
Western Blot experiment was performed, where endogenous and overexpressed 
HIPK2 were targeted. The results showed a high specificity of the antibodies for HIPK2 
(not shown). 
The next step was to check if the antibodies are able to detect small differences in the 
expression levels of endogenous HIPK2. NP40-lysates of two cell-lines (T98G and 
U373) were prepared and a BCA assay was employed to determine the protein con-
centrations. Various amounts of protein (10 µg, 20 µg, 40 µg and 80 µg) were analyzed 
by Western blotting using antibodies raised against N-terminal and C-terminal epitopes 
of HIPK2 (Fig. 4.1.1.1). The result of the Western blot shows that endogenous HIPK2 
can be detected at high sensitivity with these antibodies. 
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After the positive pretests, several cell lines were headed to Western blot (Fig. 4.1.1.2). 
The polyclonal antibody α-HIPK2 (Rab) showed the best signal and was chosen to 
compare protein expression. An increased expression of endogenous HIPK2 protein 
can be assessed in 10 out of 12 GBM cell lines (Ratio > 1), compared to HeLa cells 
(Ratio = 1). However, there is also a huge difference among the GBM cells themselves. 
The cell lines U118 and G55 show less HIPK2 protein amounts (Ratio < 1) and stand in 
contrast to the other GBM cell lines. The U373 cell line overexpresses a remarkable 
amount of the HIPK2 protein (Ratio > 2). Supporting the test reliability, two C-terminal 
antibodies (C1B3 and 5C6) show similar results in relation to the fact that they are ei-
ther not detecting C-terminal HIPK2 in U87, A172 and G55 cells, or only little amounts 
of it in U118 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.1.1: Test expression of endogenous HIPK2 with specific 
antibodies. Lysates of U373 and T98G cells were analyzed with.BCA 
assay to determine total protein levels. Different protein amounts of 10-, 
20-, 40- and 80 µg from both cell lines were investigated with N-terminal 
(N6A190) and C-terminal (C1B3) HIPK2 antibodies in Western blot ex-
periments.   
Figure 4.1.1.2: Comparative analysis of HIPK2 protein expression in tumour cell lines. HIPK2 
expression of 12 different GBM cell lines, HeLa cells and HEK-293T cells were analyzed. Equal 
amounts of NP40 lysates (=80 µg) were subjected to Western blot and endogenous HIPK2 was 
detected with different antibodies. These are either polyclonal rabbit antibodies (Rab) or monoclo-
nal antibodies raised against N-terminal (N6A10) or C-terminal (5C6, C1B3) sequences. HIPK2 
expression was quantified by using the software ImageJ®, whereas the α-HIPK2 (Rab) detected 
expression was used for calculation. The ratio was normalized to expression in HeLa cells. Actin 
served as a loading control.  
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Interestingly, the expression of HIPK2 is inconsistent when comparing the different 
antibodies in U87 and A172 cells. Ln229 cells show no signal when detecting with the 
N-terminal antibody (N6A10), whereas HEK-293T cells exhibit a strong signal. The 
limitations of this experiment are that even after changing the experiment settings for 
the N6A10 antibody, the quality did not get better. 
These findings are concluded in two main questions, which will be investigated next: 
What is the reason for the differences in endogenous HIPK2 expression in GBM and 
what role does it play in the biology of glioblastoma multiforme? 
4.1.2 mRNA levels of HIPK2 in GBM 
Since the expression of endogenous HIPK2 protein varies among GBM cell lines 
(4.1.1), it was interesting to test whether this is also reflected at the mRNA level. After 
mRNA extraction and cDNA synthesis, the relative mRNA expression of HIPK2 was 
determined by Real-time PCR. The mRNA expression of U343 cells was used as a 
reference and set to 1. A negative control was always performed using water.  
The mRNA expression of HIPK2 shows either a normal, or a slight overexpression in 
the cells U87, U343, U251, SNB, A172, A271 and G55, compared to HeLa cells. More 
interesting is the fact that U373 cells, as well as U118 cells, exhibit four to five times 
higher HIPK2 mRNA expression than other GBM cell lines. Even though U118 cells 
express low levels of HIPK2 protein (Fig. 4.1.1.2), they show a quite high HIPK2 mRNA 
expression (Fig. 4.1.2. (A).  
This experiment was repeated with several cell lines and primers, which target the C- 
and N-terminus of HIPK2. There was no significant difference in the mRNA expression 
between the C and N-terminal primers in U87, U343, A172 and 293T cells. (Fig. 4.1.2. 
(B). 
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Differences in protein amounts cannot only be due to different mRNA levels but also to 
distinct protein stabilities. This was therefore tested in further experiments. 
Figure 4.1.2: Analysis of HIPK2 mRNA expression in different GBM cell lines.  
(A) Total RNA was extracted with the RNeasy Mini kit and transcribed into cDNA using Oligo-(dT) pri-
mers. The mRNA expression was quantified by Real-time PCR using specific HIPK2 primers, which are 
targeting the conserved N-terminus (HIPK2 qRT N-term Primer3 for and rev). Actin was chosen as a 
housekeeping gene for normalization. In order to facilitate the comparison the expression of HIPK2 
mRNA in U343 was arbitrarily set to 1. All measurements were done at least n=3 times in triplicates. 
The error lines show the standard deviations. (B) According to the experimental settings in 4.1.2.A, the 
C-terminus was additionally investigated in several cell lines with HIPK2 qRT C-term for and rev primer. 
The results were compared to the mRNA expression of the N-terminal primers. 
A 
B 
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4.1.3 Protein stability of HIPK2 in GBM 
Intracellular proteins underlie a continuous proteasomal degradation process. The in-
terplay between the synthesis and degradation determines the amount of the protein in 
the cell. Since there is a discrepancy between the mRNA expression and protein level 
of HIPK2 in U118 cells, protein stability experiments using the protein translation inhibi-
tor Cycloheximide (CHX) were performed next.  
Different GBM cell lines were seeded and incubated for various periods with CHX (10 
µg/ml), followed by Western blot analysis using α-HIPK2 (Rab) antibodies (Fig. 
4.1.3.1). The results of the CHX experiments show differences in protein stability in 
GBM cell lines (Fig. 4.1.3.1). Whereas the cell lines SNB19 and G55 express a con-
stant HIPK2 level over 24 h, Ln229 and U118 cells immediately lose nearly all of their 
HIPK2 within 4 h. Especially in U118 cells, a significant loss of HIPK2 after only 2 h can 
be seen, suggesting that the HIPK2 protein is highly instable in these cells.  
 
 
 
 
 
Figure 4.1.3.1: Analysis of HIPK2 protein stability in GBM cell lines. GBM cells were harvested and 
de novo protein synthesis was blocked upon addition of Cycloheximide for various periods. Protein 
extracts were prepared followed by analysis of HIPK2 protein levels by immunoblotting with the polyclo-
nal α-HIPK2 (Rab) antibody. Actin serves as a loading control. Since U118 cells express low HIPK2 
levels, a long time exposure of the WB was additionally performed.  
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In parallel the effect of CHX treatment on the viability of fast-growing U87 cells was 
investigated. Since the cells lose the ability of adherence when they die, they can be 
mostly found in the supernatant medium. The supernatant with the dead cells and the 
adherent cells were analysed together by WB (Fig. 4.1.3.2). 
 
 
 
After 8 h of CHX treatment, two products -with molecular weights of around 90 kDa and 
105 kDa- clearly appear in the detached cells, indicating ongoing HIPK2 protein pro-
cessing.  
4.1.4 Exon analysis of HIPK2 in GBM 
Since HIPK2 was investigated at protein and mRNA levels, the next step was to check 
the exon structure of the mRNA. Previous experiments in the lab indicate two HIPK2 
isoforms in three analysed human cell lines. It was thus interesting to see whether the 
various GBM cell lines show differences in their exon usage. To address this question, 
PCR experiments with different primer pairs were performed. First, the cells were har-
vested and mRNA was extracted. Using a reverse transcriptase, the mRNA was tran-
scribed into cDNA, which was actually used as a template for the PCR experiments.  
Figure 4.1.5.A shows the exon structure of HIPK2. Annealing areas of the primers are 
highlighted with arrows. The results with the cell lines U87, A172, U343, HeLa and 
293T show one specific PCR product, with the primer pair 1F/1R and 1F/2R indicating 
no alteration in these areas (Fig. 4.1.4. (B). However, the primer pair 8F/8R leads to 
the occurrence of an additional faster migrating PCR product. This second band is less 
present in 293T cells. A second PCR product can also be detected in G55, U373, U118 
and A764 cells, when combining primer 8F/12R (Fig. 4.1.4 (C). This suggests a shorter 
product of HIPK2 at Exon 8 predominantly in GBM and HeLa cell lines.  
 
 
 
Figure 4.1.3.2: Analysis of degradation 
fragments of HIPK2 during cyclo-
heximide (CHX) treatment. U87 cells were 
harvested and treated with CHX for various 
periods. Both the supernatant and the ad-
herent cells were separately analysed us-
ing NP40-lysis and Western blotting with 
the polyclonal α-HIPK2 (Rab) antibody.  
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4.1.5 Amplification analysis of Hipk2 in GBM  
The previous results showed alterated HIPK2 protein and mRNA expression in GBM 
cell lines (Fig. 4.1.1 and 4.1.2). As genetic aberrations occur more often in malignant 
tumour cells, the idea came up that genetic amplifications should be checked, which 
might explain these alterations. For this purpose, a SNP array was performed in col-
laboration with the “Institut für Humangenetik” in Gießen. Two GBM cell lines (U373 
and U87), which showed high HIPK2 expressions in the previous experiments (Fig. 
4.1.1.2), were analysed by SNP arrays (Fig. 4.1.5). 
The results indicate a complex chromosomal aberration in chromosome 7 in GBM. The 
basal rate of log Ratio (red) on chromosome 7 is increased (0.5) and the heterozygous 
allele cluster has split into two clusters, reflecting allele proportions deviating from 1:1. 
Besides this alteration, the intensity of the log Ratio is increasing beyond the second 
half of the long arm of chromosome 7, which indicates that this area is likely amplified. 
The changes in B allele frequency (blue) and the log ratio indicate an amplification of 
B C 
A 
Figure 4.1.4: Analysis of HIPK2 exons in GBM. (A) HIPK2 mRNA exhibits 15 exons of different length. The annealing 
areas of the used primers are shown. (B) The indicated cells were grown, mRNA was extracted, and translated into 
cDNA. PCR experiments were performed with the cDNA using the indicated HIPK2 primers. Short PCR products were 
analyzed by agarose gel electrophoresis, an ethidium bromide-stained agarose gel is shown.  (C) Migration of the long-
range PCR products is displayed. 
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the region 7q32-7q35 in U373 cells and 7q31-7q35 in U87 cells. Since the Hipk2 locus 
is on 7q34 [96] its amplification in both cases is most likely. The exact copy number 
changes can be determined with the exact information about the karyotype, which 
should be further investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 4.1.5: Amplified regions on 7q in GBM including Hipk2 locus. Two GBM cell lines U373 and U87 
were harvested, DNA was extracted and amplified. A SNP array was then performed and the results were visual-
ized by KaryoStudio from Illumina. The whole chromosome 7 is mapped on the top, whereat the gene locus of 
Hipk2 (7q34) is highlighted in yellow. B Allele Frequency is shown as blue dots and log Ratio in red. 
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4.1.6 The role of HIPK2 for GBM cell proliferation  
To investigate the function of HIPK2 for proliferation of GBM cells, knockdown experi-
ments were performed. As GBM cell lines were not transfectable with cationic polymers 
they were transduced with lentiviruses encoding an shRNA mediating HIPK2 knock-
down. The lentiviruses were produced in HEK-293T cells that were transfected with the 
plasmids (PAX, pMD2.G together with shHIPK2 or shScramble). After production of 
lentiviruses, which were encoding either a HIPK2-specific shRNA or a scrambled con-
trol, GBM cells were infected. In order to achieve valid results, transfection efficiency 
and knockdown efficiency had to be checked first.  
The first step in establishing lentiviral knockdown was to find out working transfection 
efficiency: A GFP vector was used to control transfection conditions under fluorescence 
microscope. On adding 500 µl of infectious supernatant, transfection efficiency was 
regarded as sufficient (Fig. 4.1.6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
After infection of the GBM cells with the shHIPK2 or the shScramble vector, efficiency 
of the knockdown had to be determined. This can be reliably achieved by checking 
protein levels after infection. Two GBM cell lines (U87 and A172) were infected and 
non-infected cells were eliminated by puromycin selection for two or five days. A semi-
quantitative Western blot with the polyclonal HIPK2 antibody showed reduced HIPK2 
protein amounts 5 days after selection, indicating a successful knockdown (Fig. 
4.1.6.2). 
 
Figure 4.1.6.1: Cationic transfection and lentiviral infection efficiency. HEK-293T cells 
were transfected with GFP using Rotifect®. After producing lentivirus containing the GFP vector, 
GBM cells were infected and GFP expression was checked under fluorescence microscope. 
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The next step was to count the cells upon HIPK2 knockdown to observe an effect on 
cell growth. To approach this question, several GBM cell lines were infected, as de-
scribed. Starting with 2 * 106 cells, the cell numbers were determined after 2, 4 and 6 
days of selection using a FACSCalibur. A fraction of the samples was also tested for 
successful HIPK2 knockdown after 4 days of selection (Fig. 4.1.6.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.6.2: Analysis of HIPK2 knockdown efficiency in GBM cell lines. U87 and A172 cells were transfected 
with lentivirus encoding shHIPK2, shScramble or GFP. Cells were lyzed and the amount of HIPK2 was measured with 
Western Blot after 2 days and 5 days of selection. 
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Total knockdown of HIPK2 was only achieved in U118 cells, which already expressed 
only little amounts of the protein, whereas HIPK2 could be strongly down regulated in 
U87 cells, but not in U373 cells. Although the HIPK2 levels were down regulated only in 
two cell lines, the proliferation experiment showed decreased cell numbers in all three 
GBM cell lines. The drop in shScramble transfected cells after 2 days is most likely due 
to killing of non-transfected cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.6.3: Knockdown of HIPK2 expression inhibits the proliferation of GBM cells. U373, U87 and U118 
cells were infected with shHIPK2 and shScramble. Cells were counted at two-day intervals with FACS over 6 days. 
The black interrupted line represents the cells upon HIPK2 knockdown. The grey solid line shows the negative 
control upon infection with shScramble. Western Blot analysis during the fourth day was performed to show the 
knockdown success.  
Results 52 
4.2 Functional analysis of HIPK2 mutants  
4.2.1 HIPK2 mutations in cancer 
Oncogenic mutations of HIPK2 are rare, but some HIPK2 mutations were described in 
multi-dimensional and comprehensive characterization studies [144-146]. The analysis 
of the cbioportal.org showed no mutation hot spot in HIPK2, and a rather distributed 
occurrence of oncogenic mutations. Four of these mutations are located in regions of 
potential functional relevance and are displayed in figure 4.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four mutations were focused on in the following experiments. The Cancer Genome 
Atlas (TCGA) described two interesting mutations: HIPK2- R411W, (PKinase) and 
E897G (SIM) in GBM [144] and further, an amino acid change of Kidney Carcinoma at 
HIPK2 E898K (SIM) [146]. The last focus was set on the HIPK2 R833C spot (NLS2) 
from The Cancer Cell Line Encyclopedia, which was shown to be altered in breast can-
cer [145]. The mutation spots are illustrated in Figure 4.2.1. (A), including the K221A, 
ΔSIM and M1 mutant, which were also examined.  
 
 
 
 
A 
B Figure 4.2.1: Mutations of HIPK2 in 
cancer. (A) The distribution of 4 onco-
genic mutations chosen for further 
analysis in HIPK2 is shown. They 
occur in the kinase domain (HIPK2 
R411W), SIM (HIPK2 E897G and 
E898K), and NLS2 region (HIPK2 
R833C). (B) While HIPK2 R411W and 
E897G mutations were described in 
GBM, E898K was found in kidney 
carcinoma and R833C in breast can-
cer.  
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4.2.2 Construction of HIPK2 mutants and test expression 
Point mutations were introduced in vector encoding the Flag-tagged wild-type HIPK2 
protein using the Quickchange kit. The success of the mutagenesis was confirmed by 
sequencing. The mutation spots are shown in figure 4.2.2. (A). The mutants were also 
used for test expression in HEK-293T cells.  
All mutants were well expressed at the expected molecular weight (Fig. 4.2.2. (B)). 
These experiments also suggest the intact kinase activity of the oncogenic point mu-
tants, as the autophosphorylation (resulting in a retarded band) was seen for all of the 
mutants, as opposed to the K221A kinase-dead mutant which migrated faster due to 
missing autophosphorylation [147].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3 Interaction of HIPK2 mutants with SUMO1 
The SUMO interaction motif (SIM) of HIPK2 is able to bind SUMO proteins and plays 
an important role for the localization of HIPK2 in nuclear speckles [99]. It is further rele-
vant in the interaction with PML and Pc2 [148]. Since two mutants—E897G and 
Figure 4.2.2: Test expression of HIPK2 mutants. (A) Four point mutations of HIPK2 were construct-
ed in order to examine the biological effects of each. The results of the sequencing show the success 
of the mutagenesis. The bases and amino acids of interest are highlighted in red. (B) The indicated 
HIPK2 mutants were expressed in 293T cells and analyzed by Western blotting using Flag antibodies. 
The position of the unphosphorylated and autophosphorylated HIPK2 forms is shown.  
A 
B 
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E898K—are located in the SIM, it is likely to check the SUMO1 binding ability of the 
HIPK2 mutants.  
To test whether the oncogenic point mutations affect the ability to bind to SUMO1, GST 
pulldown experiments were performed. First, the GST-SUMO1 fusion protein and the 
GST control protein were expressed and purified from E.coli. Next, the pulldown was 
performed with the lysates of the Flag-tagged mutants and analyzed by Western blot 
using a specific Flag antibody. The HIPK2 ΔSIM mutant, who is lacking SIM region, 
was used as a negative control and wt Flag-HIPK2 was included as a positive control. 
The HIPK2 point mutants E897G and E898K retained their ability to interact with SU-
MO1 (Fig. 4.2.3), although both mutants are located in the SIM region (aa 884-908) of 
HIPK2. This indicates that single alterations of amino acids in the middle of the SIM 
region do not affect SUMO1 binding abilities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Interaction of HIPK2 mutants with PIN1 
The phospho-specific isomerase PIN1 is binding to autophosphorylated HIPK2 [149]. It 
inhibits HIPK2 polyubiquitination and leads to a decrease of proteasomal degradation 
processes, thus modulating HIPK2 and Siah-1 interaction [104]. In order to investigate 
whether the mutant R411W in the protein kinase region of HIPK2 affects the interaction 
with PIN1, a GST-pulldown experiment was performed using GST-PIN1. GST pull-
Figure 4.2.3: Functional analysis of SU-
MO1 binding of HIPK2 and its mutant 
versions. HEK293T cells were transfected 
to express Flag-tagged HIPK2 and its mu-
tants. Cell extracts were prepared. While 
10% of the material was used for the input 
control, the remaining material was incubat-
ed with GST-SUMO1 or the GST control to 
allow binding. After several washes and 
elution, the GST and its associated HIPK2 
proteins were analyzed by Western blotting. 
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down experiments showed PIN1 binding by the HIPK2 mutants R826C, E890G, E891K 
and ΔSIM). In contrast, the HIPK2 K221A negative control showed as expected almost 
no interaction and the mutant and HIPK2 R411W showed a significantly impaired bind-
ing (Fig. 4.2.4). This finding suggests that R411W retains a residual kinase activity, 
although being less active than the wild-type kinase.  
 
 
 
 
 
 
 
 
 
 
 
 
4.2.5 Enzymatic kinase activity of HIPK2 mutants 
To test the kinase activity of the oncogenic HIPK2 mutants, several [87, 150] HIPK2 
mutants were co-transfected with Flag tagged version of the HIPK2 substrate protein 
MEF2D, which is a substrate of HIPK2. Cell lysates were prepared and analyzed by 
Western blotting. All mutants retained the ability to phosphorylate the substrate protein 
MEF2D, as visible by the occurrence of a phosphorylated and slower migrating MEF2D 
band. The results indicate that none of the mutants, including the mutation HIPK2 
R411W, affects the enzymatic activity of HIPK2 (Fig. 4.2.5). 
 
 
 
 
 
 
Figure 4.2.4: Functional analysis of PIN1 
binding of HIPK2 and its mutant versions. 
HEK-293T cells were transfected to express 
Flag-tagged HIPK2 and its mutants. Cell 
extracts were prepared. While 10% of the 
material was used for the input control, the 
remaining material was incubated with GST-
PIN1 or the GST control to allow binding. After 
several washes and elution, the GST and its 
associated HIPK2 proteins were analyzed by 
Western blotting. K221A was used as a nega-
tive, wild-type (wt) as a positive control.  
Figure 4.2.5: Enzymatic activity of HIPK2 mutants. After co-transfection of HIPK2 mutants 
with Flag-MEF2D, cells were lyzed and headed to Western Blot using α-Flag antibody. Kinase 
dead mutant HIPK2 K221A serves as a negative control and HIPK2 wt as a positive control.  
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4.2.6 Subcellular localization of HIPK2 mutants 
HIPK2 is a protein that is mostly located in subnuclear speckles [99, 101]. Through a 
SUMO interaction motif (SIM), it is able to bind three isoforms of SUMO (1–3), while 
only SUMO1 is binding covalently [151-153]. This posttranslational modification and 
also an intact SIM are required for the localization of HIPK2 in subnuclear speckles 
[101]  [99]. Since two of the mutations are found in the SIM area (HIPK2 E897G, HIPK2 
E898K), it was interesting to test their influence on the subcellular localization of 
HIPK2. In addition, I testes the intracellular localization of the HIPK2 R833C mutant 
that is found in NLS2. To test the intracellular localization of HIPK2 and its mutants, 
U2OS osteosarcoma cells were transiently transfected to express several constructs 
Flag-tagged HIPK2 variants. After two days, cells were analyzed by immunofluores-
cence using Flag antibodies. 100 transfected cells were randomly chosen for the anal-
ysis of the intracellular localization of each mutant. Samples were blinded and localiza-
tion was categorized as displayed in figure 4.2.6. A. Cells were categorized in four 
groups: HIPK2 in a) nucleus with speckles, b) nucleus without speckles, c) entire cell 
with speckles and d) entire cell without speckles. In collaboration with Anita Höland 
from the statistical institute “Arbeitsgruppe Medizinische Statistik” in Gießen a Chi-
square test was performed to determine statistical independency, representative re-
sults are shown in figure 4.2.6. B. The results are shown in table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subcellular localization Significance 
HIPK2 wt 39,4 % of P1 p < .001 
HIPK2 ∆SIM  34,6 % of P2 p = .036 
HIPK2 K221A 67,6 % of P1 p < .001 
HIPK2 E897G 45,4 % of P1 p < .001 
HIPK2 E898K 49,5 % of P4 p < .001 
HIPK2 R833C 52,9 % of P4 p < .001 
Table 2:  Subcellular localization of HIPK2 and its mutants 
Table 2: Subcellular localization of HIPK2 mutants. The percental distribution 
of subcellular localization for HIPK2 and its mutants is shown. Four different pos-
sible localizations (P1-P4) are evaluated as according to figure 4.2.6. (A). The 
distribution was determined with a Chi-square test. The significance is shown as 
p-value.  
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Figure 4.2.6: Subcellular localization of HIPK2 mutants. (A) Schematic representation 
of four different possible cellular localizations (P1-P4) of HIPK2. (B) U2OS cells were 
transfected to express the indicated HIPK2 proteins and analyzed by immunofluores-
cence. Nuclear DNA was stained with Dapi and is shown in blue. Green tags represent 
Flag-HIPK2. 200 cells were blindly evaluated and the percental distribution was evaluated 
in which the most common cellular localization is shown on the right. The p-value repre-
sents the statistical significance.  
 
A 
B 
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5 Discussion 
Applied medicine helps people to live much longer than they did in the past. But older 
organisms have a statistically increased risk to undergoing the inactivation of tumour-
suppressors or the activation of proto-oncogenes through genetic and epigenetic 
mechanisms, resulting in the neoplastic transformation of cells [154]. This development 
increases the incidence of cancer, which is a new challenge for medical research. The 
progress in fundamental molecular biological research over the past years has been 
crucial for a great deal of achievements in tumour therapy. A milestone in this devel-
opment is the characterization of the oncogenic fusion protein BCR-ABL1 and the con-
struction of its inhibitor, Imatinib. Many patients with chronic myeloid leukemia (CML) 
and gastrointestinal stromal tumours (GIST) have benefited from this therapy. Modern 
attempts focus on the construction of monoclonal antibodies, which have been specifi-
cally designed to target certain antigens on tumour cells. Some of the examples are: 
Rituximab targeting CD20 in Non-Hodgkin's lymphoma, Trastuzumab targeting ERBB2 
in breast cancer, or Ipilimumab targeting CTLA4 in metastatic melanoma [155]. These 
developments would not have been possible without the precise characterization of 
disease-causing molecular events. Even though GBM is the most lethal brain tumour, 
we do not know much about its intracellular alterations and thus cannot choose the 
potential candidates for modern drug therapies. In order to identify more factors in-
volved in gliomagenesis, this study focuses on the tumour suppressor HIPK2, which is 
strongly expressed in the brain and neurons [90] and, which plays an important role in 
apoptosis, cell cycle regulation and DNA damage responses [156].  
5.1 The expression of HIPK2 is dysregulated in GBM 
Various studies have shown a dysregulated HIPK2 in neoplastic thyroid carcinoma, 
breast cancer, and well-differentiated thyroid carcinoma, as well as in pilocytic astrocy-
toma [127]. My experiments have revealed a highly dynamic HIPK2 expression in vari-
ous GBM cell lines.  
Performing semi-quantitative Western blot experiments, I could show strong variations 
in HIPK2 protein levels in GBM cell lines. As the cultivation of healthy human astro-
cytes is difficult, the expression levels were compared with non-GBM cell lines (HeLa 
and 293T cells). The relative expression of HIPK2 protein was quite variable. In direct 
comparison to HeLa cells, U118 and G55 cell lines show reduced HIPK2 levels, while 
most of the GBM cell lines (82 %) exhibit an increased HIPK2 expression (Fig. 4.1.1.2). 
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This finding corresponds to the finding in Grade I brain tumours (pilocytic astrocytoma), 
where an overexpression of endogenous HIPK2 was described [126]. Deshmukh et al. 
(2008) have also performed statistical analysis with primary cells and detected an 
overexpression of HIPK2 in only 23 % of Grade III (anaplastic astrocytoma) tumours 
and in 27 % of Grade IV (GBM) tumours [126]. There are three possible explanations 
for these divergent findings between the results of my study and the results obtained by 
Deshmukh et al.:  
1) Deshmukh et al. have used primary cell lines for their studies. Primary cells can 
show a different behaviour than that of the cultivated cell lines, which undergo a 
continuous changing process during subcultivation [157].  
2) In contrast to this study, where GBM cells have been compared to HeLa (cervix 
carcinoma) and 293T (human embryonic kidney) cells, Deshmukh et al. have 
compared GBM glial cells with non-malignant, healthy brain tissue.  
3) Since the sub-classification of GBMs can also be amended by the inclusion of 
molecular markers [158], I might have investigated different subtypes than 
those handled by Deshmukh et al. Therefore, the complexity of GBM demands 
a higher degree of sub-classification. A promising approach can be seen in 
Verhaak et al. (2010), who have identified clinically relevant subtypes of GBM 
by including the expression patterns of EGFR, IDH1, NF1, and PDGFRA [10]. 
However, a confounding factor is the further evolution of subtypes that can 
change to other subtypes [158]. It would be interesting to see whether HIPK2 
expression levels can be helpful in the classification of different GBM subtypes.  
In principle, the dynamic HIPK2 expression can be attributed to different mechanisms 
including genomic changes, such as gene amplification and LOH, as well as to tran-
scriptional, post-transcriptional, translational and post-translational events. 
5.2 Mechanisms of HIPK2 dysregulation in GBM 
To investigate the molecular mechanisms of the HIPK2 dysregulation in GBM, I ex-
plored different steps of protein synthesis.  
The first mechanism that I found was an amplification of the HIPK2-encoding locus. 
The results from SNP array experiments showed an amplification of the Hipk2 gene in 
a locus spanning from 7q32-7q35 in U373 cells and 7q31-7q35 in U118 cells including 
the Hipk2 locus at 7q34 (Fig. 4.1.5). An additional FISH experiment is further needed to 
identify the exact karyotype. Since the B-Raf gene is also located in the amplified ge-
nomic region at 7q34, it is possible that B-Raf-derived signaling cascades contribute to 
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the oncogenic transformation of these cell lines [159]. However, this coincidence could 
be the reason-apart from pilocytic astrocytoma [126, 127] - that the HIPK2 locus was 
neglected in the past. A copy number gain of Hipk2 has been described in a study, 
where 41 out of 63 patients with Grade I tumours (pilocytic astrocytoma) showed Hipk2 
amplifications [126].  
The next step in protein synthesis is the transcription of DNA into mRNA and therefore 
the mRNA expression was investigated with qPCR experiments. The relative mRNA 
expression in GBM cells showed significantly, around fivefold, increased HIPK2 mRNA 
levels in two out of nine GBM cell lines (U373 and U118) than in to other GBM and the 
HeLa and 293T control cell lines (Fig. 4.1.2). Since the Hipk2 locus was amplified in 
U373 cells, this could be a reasonable explanation for its increased mRNA levels. In-
creased Hipk2 mRNA levels have also been described in low Grade I tumours, and a 
linear correlation between the Hipk2 gene amplification and the increased mRNA levels 
in the same tumour was shown as well [126].  
Protein stability experiments have shown that HIPK2 protein is highly unstable in U118 
and Ln229 cells, as the protein was absent already two hours after the inhibition of pro-
tein translation (Fig. 4.1.3.1). In the course of CHX experiments, I noted two HIPK2-
reactive bands in extracts prepared from detached cells (Fig. 4.1.3.2). These products 
may represent degraded the HIPK2 products of dying or dead cells in the supernatant. 
The quantity of these two bands is higher after eight hours and diminishes 24 hours 
after CHX treatment-this reflects the fact that the floating cells are already dead at the 
late time point.  
In brief, dysregulation and a high volatility of HIPK2 levels were found in different GBM 
cell lines. This study shows that different molecular mechanisms account for the varia-
bility in the HIPK2 expression.   
To illustrate the “multiform” aspect of glioblastoma multiforme, I will exemplary show 
the dysregulation of HIPK2 by the two varying GBM cell lines U373 and U118 (Table 
3). 
• U373 cells exhibit an amplified Hipk2 locus, increased HIPK2 mRNA, in-
creased HIPK2 protein levels and unaffected protein stability. It is reasonable 
to suppose that the amplified Hipk2 locus leads to increased HIPK2 mRNA and 
thus protein levels. 
• U118 cells also show increased HIPK2 mRNA, but relatively low HIPK2 protein 
levels and increased HIPK2 protein degradation. The Hipk2 locus was not in-
vestigated in U118 cells: however I assume it to be of the wild-type. 
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The increased protein degradation in U118 likely accounts for the reduced levels of the 
endogenous HIPK2 protein. It will be interesting to investigate whether impaired HIPK2 
protein levels would lead to a compensatory induction of Hipk2 transcription (Fig. 
5.1.1). Similarly, the stability of HIPK2 mRNAs could be altered in U118 cells and other 
GBM cell lines. Further experiments are needed to address these questions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 U373 U118 
Hipk2 locus 7q34+ n.D. 
HIPK2 protein amount 
  
HIPK2 mRNA amount 
  
HIPK2 protein stability 
  
↑↑ ↓↓ 
↑↑ ↑↑ 
↔ ↓↓ 
Figure 5.1: Two possible mechanisms leading to HIPK2 dysregulation in U373 and U118 cells. The amplified 
HIPK2 region in U373 cells might lead to increased mRNA and thus protein levels of HIPK2. In U118 cells however, 
decrease in protein stability leads to low levels of HIPK2 protein, which might induce the transcription of Hipk2 and 
thus could explain the increased mRNA expression.  
Table 3: Dysregulation of HIPK2 in U373 and U118 cells 
Table 3: Dysregulation of HIPK2 
in U373 and U118 cells.  
Hipk2 amplified in U373 cells and 
not determined (n.D.) in U118 cells. 
↑↑ = highly upregulated  
↓↓ = highly downregulated  
↔ = no dysregulation  
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Another interesting observation is the fact, that the Hipk2 gene locus is amplified in 
U87 as well as in U373 cells (Fig. 4.1.5. (B), but only U373 cells seem to express high-
er HIPK2 mRNA and protein levels when compared to U87 cells (Fig. 4.1.1.2 and Fig. 
4.1.2. (A). In the following, I will discuss two explanations for this observation:  
1) The p53 status of the cells: The investigated cell line U373 was shown to ex-
press mutant p53 (Arg272Gln), whereas U87 cells exhibit the wild-type p53 [1]. 
It was also shown that expression of the endogenous mutant p53 in SNB19 and 
U373 GBM cell lines have an impact on cell survival and may lead to increased 
colony formation [163]. Usually, p53 is an inducible protein that accumulates in 
the cells after DNA damage [164]. The mutant p53 shows an impaired auto-
regulation with its negative regulators like Mdm2 and accordingly leads to the 
accumulation of the mutant p53 even in unstressed cells [165]. Since evidence 
increasingly indicates an influence of the mutant p53 on the gene expression 
[166, 167], it would be interesting to investigate whether the transcription of 
Hipk2 is affected directly or indirectly from the mutant p53. It is conceivable, that 
the oncogenic effects of the mutant p53 can be partly mediated through the 
dysregulation of HIPK2 protein levels or direct protein-protein interactions.  
2) As HIPK2 protein levels are controlled by different steps necessary for its syn-
thesis and also decay, so-far unknown and uninvestigated regulatory steps may 
account for differential protein levels. For example: The dysregulation of pro-
teins that can interact with HIPK2 and influence its stability has already been 
described in the literature [168]. It would be interesting to investigate further E3-
ligases, such as Siah-1 and Siah-2, in the context of HIPK2 dysregulation and 
GBM.  
Taken together, GBM cells seem to have highly divergent levels of the HIPK2 protein. 
Even though HIPK2 amounts are strongly variable in various cell lines, different mech-
anisms contribute to the HIPK2 dysregulation in GBM. These results also put a cau-
tionary note on many deep-sequencing and genome-wide association studies [169] 
that describe only the genomic levels of potential tumour regulators. My results show 
that high mRNA levels do not necessarily correlate with high protein levels and vice 
versa. Since proteins are responsible for cellular and extracellular functions, it is nec-
essary to investigate changes at the genomic as well proteomic levels. The following 
figure summarizes the results of my experiments (Fig. 5.1.3). 
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5.3 The role of HIPK2 in GBM cell proliferation  
In the literature, HIPK2 has been postulated as a tumour suppressor [170]. Its knockout 
in Hipk2-/- mice mutants can lead to cancer development, cancer progression, in-
creased tumour formation, metastatic potential and resistance to chemotherapy[120, 
171]. In this study, the functional role of HIPK2 was studied by determining the prolifer-
ation of cells after the knockdown of HIPK2. The lentiviral knockdown of HIPK2 in 
U373, U87 and U118 cell lines led to a massive collapse of cell proliferation (Fig. 
4.1.6.2). The impact of HIPK2 deficiency on cell viability occurs already two days after 
the transfection of the shRNA encoding plasmid. While HIPK2 knockdown abolishes 
the proliferation of U373 and U118 cell lines, its impact on cell proliferation was less 
severe in U87 cells: Around 500,000–1 million U87 cells survived the knockdown 
treatment. These findings show that HIPK2 knockdown has differential effects on the 
various cell lines tested.  
The differential effects of HIPK2 on cell proliferation and viability could be due to sev-
eral reasons.  
Most of the cells in this study could not fully reach HIPK2 knockdown, whereas the 
knockout mice described by Isono et al completely lack HIPK2 [89]. It is possible that 
decreased levels of HIPK2 protein might harm the cell and cause apoptosis [97, 101], 
while the complete lack of HIPK2 is compensated by other members of the HIPK family 
[89]. Another paper shows that HIPK2 knockdown increases the increased proliferation 
of mouse embryonic fibroblast (MEF) cells [149]. The discrepancy could be due to the 
use of different cells from different species or potential off-target effects of the shRNA. 
Further studies are required to clarify the consequences of HIPK2 knockdown in a sys-
tematic manner.  
a) Isono et al. (2006) have shown that Hipk2 deficient mice had no relevant defi-
cits [89]. But a few methodical differences with my study can be found. Isono et 
al. have performed a knockout and worked with a mouse model. I did a lentiviral 
knockdown, treated cell lines and focussed on human GBM. So, species-
specific differences and differences in the knockout or knockdown response be-
tween mice and human cannot be excluded. 
b) Furthermore, by considering that some GBM cell lines overexpressed endoge-
nous HIPK2 and amplified Hipk2, it could be possible that HIPK2 plays an addi-
tionally independent role in GBM tumour-biology. Several studies have also de-
scribed the amplification of Hipk2 in low-grade astrocytoma [126, 143, 159]. 
Further experiments are needed to ascertain if the knockdown specifically af-
fects tumour cells that are addicted to the overexpression of HIPK2 (Fig. 4.1.7). 
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A reasonable approach could be the complementary use of another method for 
HIPK2 downregulation. A modern approach is the CRISPR-Cas9 system, which 
can precisely cleavage at endogenous genomic loci [173]. Also, a negative con-
trol with healthy cells should be performed. 
Interestingly, U118 cells, which express low basal HIPK2, and U373 and U87 cells ex-
pressing high basal levels of HIPK2 failed to survive the treatment with the knockdown 
vector shHIPK2 (Fig. 4.1.6.3). In contrast, the impact of HIPK2 downregulation on cell 
survival was only minor in U87 cells, indicating that probably a subset of tumour cells 
rely on HIPK2-dependent functions. 
The differential effects of HIPK2 protein amount variations can be considered with re-
spect to the suggested “optimum model” [174]. This postulated model suggests that a 
disease can be caused by deviant HIPK2 amounts - either too little or too much. Ac-
cording to this suggestion, only an optimum amount of HIPK2 ensures sufficient func-
tion, while higher concentrations of HIPK2 inactivates the protein probably due to mis-
folding or inactive protein aggregates [174]. 
5.4 Functional analysis of HIPK2 mutants occurring in tumours  
Only a few mutations of HIPK2 have been described. In 2007, two Hipk2 missense 
mutations (R868W and N958I) were described in human acute myeloid leukemia cells. 
These mutants affected their nuclear localization [124]. It is not clear whether mutations 
in the Hipk2 gene are relevant for tumourigenesis or a consequence of genomic insta-
bility, which is typically observed in tumour cells [175]. Further multidimensional and 
comprehensive characterization studies of primary GBM cells, kidney renal clear cell 
carcinoma and breast cancer cells, as summed up on the cancer portal cbioportal.org, 
were able to find several mutations of HIPK2 [144]. However, these studies have not 
investigated the effect of the Hipk2 mutations on the functionality or localization of 
HIPK2.  
In the second part of my work, I investigated the selected Hipk2 mutations occurring in 
regions that might affect functional regions including the protein kinase domain, NLS2, 
and the SIM region. The mutations were reconstructed by mutagenesis, and their func-
tional behaviour was analyzed after the expression in 293T-HEK cells. The results of 
these experiments can be interpreted in the context of a wild-type control.    
The first mutation, which I examined, was HIPK2 R411W. This mutation has been de-
scribed in GBM and is located in the protein kinase domain [144]. In the following, I will 
discuss the investigated effects of HIPK2 R411W mutation on a) transphosphorylation 
and b) autophosphorylation. 
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a) As the protein kinase domain of HIPK2 is necessary for the phosphorylation of 
several target proteins, such as p53 or MEF2D, it was interesting to check the 
transphosphorylation abilities of HIPK2 R411W. This was achieved by the co-
transfection of miscellaneous HIPK2 mutants with a Flag-tagged MEF2D. 
Western blotting showed an upshifted band in HIPK2 R411W, which corre-
sponds to a phosphorylated MEF2D protein (Fig. 4.2.5). So, the HIPK2 R411W 
mutant seemed to retain its MEF2D transphosphorylation abilities.  
b) I also investigated the autophosphorylation abilities of HIPK2 R411W. Since the 
autophosphorylation of HIPK2 was shown to be crucial for PIN1-binding [149], 
GST-pulldown experiments with GST-PIN1 and several HIPK2 mutants were 
performed in order to indirectly measure the HIPK2 autophosphorylation capa-
bility. Actually, the results showed an impaired HIPK2 R411W and PIN1 binding 
when compared to the wild-type HIPK2 (Fig. 4.2.4), a reduced autophosphory-
lation. The interaction between PIN1 and HIPK2 was also shown to stabilize 
HIPK2 protein and prevent it from degradation [104]. Since I could show altera-
tions in the HIPK2 degradation in GBM (Fig. 4.1.3.1), the mutation of HIPK2 
R411W may play a role in HIPK2 protein stability and should be checked espe-
cially in GBM cell lines with increased HIPK2 degradation such as U373, Ln229, 
and U118 (Fig. 4.1.3.1). 
My experiments could show that the PIN1 binding ability was partly affected by the 
HIPK2 R411W mutation (Fig. 4.2.4), indicating reduced autophosphorylation ability. 
Since HIPK2 and PIN1 binding depends on the autophosphorylation of HIPK2 [104], it 
can be assumed that the HIPK2 R411W mutant in the kinase region is less active than 
the wild-type kinase, even tough it remains a residual kinase activity. 
The mutants I investigated next were HIPK2 E897G and E898K, which are located in 
the C-terminal SIM region of HIPK2. Since both mutations are close to each other and 
were described in two different cancer studies for GBM (E897G) and kidney carcinoma 
(E898K) [144, 146], this region seemed to be a promising candidate in terms of func-
tional relevance. The SIM region is important for HIPK2 and serves as a docking motif 
for SUMO proteins and promotes protein-protein interaction networks [176]. SUMO-
binding to HIPK2 also plays a role in the subcellular localization of HIPK2 in nuclear 
speckles [176]. So, I investigated the mutants HIPK2 E897G and E898K relating to a) 
SUMO1-binding and b) nuclear localization. 
a) The binding abilities of the HIPK2 mutants with SUMO1 were determined with 
GST-pulldown experiments. A mutant lacking the whole SIM region was used 
as a control. The results could not show any impact of the mutants HIPK2 
E897G and E898K on SUMO-binding (Fig. 4.2.3). It seems that the mutation of 
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only one amino acid in the SIM region is not sufficient to affect the SUMO-
binding capability of HIPK2. Interestingly, the literature shows that HIPK2 muta-
tions of the whole range aa 885-892 and 893-899, impair the SUMO1-binding 
ability [177].  
b) The subcellular localization of HIPK2 mutants was determined with immunofluo-
rescence. Therefore, U2OS osteosarcoma cells were transfected with the mu-
tants HIPK2 E897G and E898K. The results showed that most of the HIPK2 
E897G mutants could co-localize their HIPK2 in nuclear speckles. However in 
contrast, the HIPK2 E898K mutants spread their HIPK2 mostly throughout the 
entire cell (Fig. 4.2.6). Hence, the HIPK2 mutation E898K might impact the sub-
cellular localization of HIPK2, even though its SUMO-binding ability is not im-
paired (Fig. 4.2.3). This raises the question as to mechanisms other than the 
SUMO-binding capability could contribute to a mislocalization of the mutant 
HIPK2 E898K.  
The last mutant I examined was HIPK2 R833C, which was described in breast cancer 
[145]. This mutant is located in the NLS2 region of HIPK2. The literature shows, that 
HIPK2 has two NLS sequences, namely NLS1 and NLS2 [177]. Only one mutation of 
an amino acid in NLS2 is needed for inactivation, while two mutations of residues in 
NLS1 are required. This indicates that NLS2 is more important for the localization of 
HIPK2 than NLS1. So I hypothesized that the mutant HIPK2 R833C in NLS2 would 
affect subcellular localization. According to the literature, most of the mutants failed to 
localize in the nucleus and could be detected throughout the entire cell in nucleoplas-
ma (Fig. 4.2.6). However, a small fraction still could be seen in the nucleus, probably 
due to an interaction of the SIM region in nuclear speckles.  
In summary, the results from this section show that the HIPK2 variants with the exam-
ined mutations retain most of their functions, but they do display some differences con-
cerning their intracellular localization (HIPK2 R833C) or PIN1-binding ability (HIPK2 
R411W). However, it can be assumed that the observed mutations are likely due to 
genomic instability rather than a driver for tumourigenesis. 
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Summary 
Glioblastoma multiforme (GBM) is a primary CNS neoplasm and the most common, 
aggressive and malignant brain tumour in adults. Even though many studies have been 
performed on its pathological genetics and molecular pathways, there is currently no 
possible cure. The aim of this study was to investigate the role of the serine/threonine 
kinase homeodomain interacting protein kinase 2 (HIPK2) in the pathology of GBM. A 
variety of experimental approaches revealed strong variations in HIPK2 protein expres-
sion levels. My work showed that these expression changes are due to a variety of 
factors including gene amplification (U373 and U87 cells), mRNA expression and pro-
tein stabilities. Further proliferation experiments showed that GBM cell lines (U373, 
U87 and U118 cells) stop growth upon the lentiviral HIPK2-knockdown. These results 
suggest that at least some GBMs depend on HIPK2 for their proliferation. In parallel, 
this study analyzed the functional consequences of HIPK2 mutations that were detect-
ed in tumour cells. HIPK2 expression vectors carrying these mutations were generated 
and tested for their localization, kinase activity and for their ability to interact with the 
SUMO protein and the prolyl isomerase PIN1. No major differences in all these param-
eters were observed - this suggests that the functional role of HIPK2 in oncogenesis is 
due to its relative expression levels.  
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Zusammenfassung  
Glioblastoma multiforme (GBM) ist eine primäre Neoplasie des zentralen Nervensys-
tems und der häufigste, aggressivste und bösartigste Gehirntumor beim Erwachsenen. 
Trotz zahlreicher genetischer, molekularbiologischer Experimente, sowie klinischer 
Studien, gibt es zurzeit keine Möglichkeit auf Heilung. Das Ziel dieser Studie war es, 
die Rolle der Serin-Threonin-Kinase Homeodomain interacting protein kinase 2 
(HIPK2) in der Pathogenese des GBM zu untersuchen. Die Experimente zeigten ins-
besondere eine fehlregulierte HIPK2 Proteinexpression und es gelang mir zu belegen, 
dass diese Fehlregulierung auf unterschiedliche Faktoren, wie Genamplifikation (U373 
und U87 Zellen), mRNA-Expression und Proteinstabilität zurückzuführen sind. Weiter-
hin zeigten Proliferationsexperimente, dass GBM Zelllinien (U373, U87 und U118 Zel-
len) während eines lentiviralen Knockdowns von HIPK2 aufhören zu wachsen. Diese 
Ergebnisse lassen vermuten, dass das GBM Wachstum von HIPK2 abhängig ist. 
Gleichzeitig untersuchte ich die Auswirkungen von HIPK2 Mutationen, die bei Tumor-
zellen detektiert wurden. Dafür wurden HIPK2 Vektoren generiert, die diese Mutationen 
enthalten und die Auswirkungen auf die Lokalisation, Kinase-Aktivität und die Interakti-
onsfähigkeit mit SUMO Proteinen, sowie der Prolyl-Isomerase PIN1 untersucht. Hierbei 
zeigten sich keine großen Unterschiede in den beobachteten Parametern, weswegen 
sich die onkogene Rolle von HIPK2 in der relativen Expression vermuten lässt.  
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List of abbreviations 
 
% (v/v) Volume/volume percentage  
% (w/v) Weight/volume percentage  
5-ALA 5-aminolevulinic acid 
A-bomb Atomic bomb 
aa Amino acid 
AD Alzheimer's disease 
Akt see PKB 
AML Acute myeloid leukemia 
AMPKα AMP-activated protein kinase alpha 
APS Ammonium persulfate 
ATCC American Type Culture Collection 
ATRX Alpha thalassemia/mental retardation syndrome x-linked 
BAX BCL2-associated X protein 
BCA Bicinchoninic acid assay 
BRAF B-raf proto-oncogene 
CA Carcinoma 
CCDC Coiled-coil domain-containing protein 
CDK Cyclin-dependent kinase 
CDKN Cyclin-dependent kinase inhibitor 
CHX Cycloheximide 
CIC Capicua transctiptional repressor 
cRNA Complementary DNA 
CT Computed tomography 
CtBP C-terminal binding protein 
CTLA Cytotoxic T-lymphcyte-associated protein  
Da Dalton 
DAXX Death-domain associated protein 
ddH2O Double-distilled water 
dsDNA Double-stranded DNA 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsDNA Double-stranded DNA 
DTT Threo-1,4-dimercapto-2,3-butanediol  
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DYRK Dual-specificity tyrosine-phosphorylation regulated kinase 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERBB Erb-b2 receptor tyrosine kinase 2 
et al. et alii (and others) 
FACS Fluorescence activated cell sorting 
FUBP Far upstream element (FUSE) binding protein 
GBM Glioblastoma multiforme 
GFP Green fluorescent protein 
GST Glutathione S-transferase 
GTP Guanosine-5-triphosphate 
Gy Gray 
h hours 
H2B Histone 2B 
HIF-1α Hypoxia inducible factor 1, alpha subunit 
HIPK Homeodomain-interacting protein kinase 
HNPCC Hereditary nonpolyposis colorectal cancer 
HPV Human papillomavirus 
IARC International Agency for Research on Cancer 
IDH1 Isocitrate dehydrogenase 1 
IPF Idiopathic pulmonary fibrosis 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IR Infrared (radiation) 
JNK Janus kinase 
L1CAM L1 cell adhesion molecule 
LB Lysogeny broth 
LEF Lymphoid enhancer-binding factor 
LOH Loss of heterozygosity 
MAPK Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
MDM2 Mouse double minute 2 homolog 
MDS Myelodysplastic syndrome 
MEF2D Myocyte enhancer factor 2D 
MEK see MAPKK 
MGMT O-6-methylguanine-DNA methyltransferase 
miR microRNA 
mRNA messenger DNA 
MRT Magnetic resonance tompgraphy 
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mTOR Mechanistic target of rapamycin 
Mut mutation or mutated 
NF- κB Nuclear factor of kappa light polypeptide gene enhancer B-cells 1 
NF1 Neurofibromatosis 1 or neurofibromin 1 
NF2 Neurofibromatosis 2 
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
NLS Nuclear localization signal 
NP-40 Nonidet P40 
NTP Nucleoside triphosphate 
PA Pilocytic astrocytoma 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PC2 Polycomb protein 2 
PCAF P300/CBP-associated factor 
PEBP Phosphatidylethanolamine binding protein 
PEI Polyethylenimine 
PEST peptide sequence rich in proline (P), glutamic acid (E), serine (S) and 
threonine (T) 
PET Positron emission tomography 
PHLDB Pleckstrin homology-like domain, family b 
PI3KCA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)  
PIN Peptidylprolyl cis/trans isomerase, NIMA-interacting 
PIP2 Phosphatidylinositol (4,5)-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PKB Protein kinase b 
PKinase Protein kinase  
PML Promyelocytic leukaemia (nuclear bodies) 
PMSF Phenylmethanesulfonyl fluoride 
PTEN Phosphatase and tensin homolog 
PUMA p53 upregulated modulator of apoptosis 
PVDF Polyvinylidene fluoride 
qPCR Real-time quantitative polymerase chain reaction 
Raf Rapidly accelerated fibrosarcoma (gene) 
Ras Rat sarcoma (gene) 
RB1 Retinoblastoma 1 
rpm rounds per minute 
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RTEL Regulator of telomere elongation helicase  
RTK Receptor tyrosine kinase 
RUNX Runt-related transcription factor 
SCFFbx3 Skp, Cullin, F-box containing complex, F-box protein 3 
SDS Sodium dodecyl sulfate 
shRNA Short-hairpin RNA 
Siah Siah E3 ubiquitin protein ligase 
SIM SUMO-interacting motif 
SMMHC Smooth muscle myosin heavy chain 
SNP Single nucleotide polymorphism 
SPECT Single-photon emission computed tomography 
ssDNA Single-stranded DNA 
STAT Signal transducer and activator of transcription 
SUMO Small ubiquitin-like modifier 1 
Sv Sievert 
TBS-T Tris-buffered saline and tween 
TCGA The Cancer Genome Atlas 
TEMED N, N, N', N'-Tetramethylethylendiamine 
TERT Telomerase reverse transcriptase 
TGF-β Transforming growth factor, beta 1 
TIMP3 Metallopeptidase inhibitor 3 
TMZ Temozolomide 
TP53 Tumour protein p53 
TSC Tuberous sclerosis 
UTR untranslated region 
UV Ultraviolet (radiation) 
V Volt 
VEGF Vascular endothelial growth factor 
WB Western blot 
WHO World Health Organization 
WIP Wild-type p53-induced phosphatase 
WSB WD repeat and SOCS boy containing 
wt Wild-type 
X-ray X-radiation 
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